Chimeric bovine embryo multiplication with OCT4 knockout host embryos by Simmet, Kilian Manuel
  
 
 
 
 
Chimeric bovine embryo multiplication 
with OCT4 knockout host embryos 
 
 
 
 
 
 
 
 
 
von Kilian Manuel Simmet 
 
 
 
 
 
  
Inaugural-Dissertation zur Erlangung der Doktorwürde 
(Dr. rer. biol. vet.) 
der Tierärztlichen Fakultät der Ludwig-Maximilians-Universität 
München 
 
 
 
 
 
Chimeric bovine embryo multiplication 
with OCT4 knockout host embryos 
 
 
 
 
von Kilian Manuel Simmet 
aus Valdivia / Chile 
 
 
 
München 2017 
 
 
Aus dem Veterinärwissenschaftlichen Department der Tierärztlichen 
Fakultät der Ludwig-Maximilians-Universität München 
 
 
 
Lehrstuhl für Molekulare Tierzucht und Biotechnologie 
 
 
 
Arbeit angefertigt unter der Leitung von Univ.-Prof. Dr. Eckhard Wolf 
 
 
Mitbetreuung durch: Dr. Nikolai Klymiuk und Prof. Dr. Valeri 
Zakhartchenko 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Tierärztlichen Fakultät 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
Dekan:    Univ.-Prof. Dr. Joachim Braun 
 
 
Berichterstatter:           Univ.-Prof. Dr. Eckhard Wolf 
 
 
Korreferent/en:         Prof. Dr. Sabine André 
  Priv.-Doz. Dr. Petra Kölle 
  Univ.-Prof. Dr. Dr. h.c. Hans-Joachim Gabius 
  Univ.-Prof. Dr. Gerd Sutter 
 
 
Tag der Promotion:  11.02.2017
  
 
 
 
 
 
 
 
 
 
 
Meinen lieben Eltern 
 
  
Table of contents   I 
TABLE OF CONTENTS 
I. Introduction .......................................................................................................... 1 
II. Review of Literature ............................................................................................ 3 
1. Chimeric embryos ............................................................................................ 3 
2. Multiplication of embryos through chimeric complementation....................... 6 
3. Use of phytohemagglutinin-L for embryo aggregation ................................... 7 
4. The pluripotency regulating transcription factor OCT4................................... 8 
4.1 Oct4 in the preimplantation mouse embryo ............................................... 9 
4.2 OCT4 in the preimplantation bovine embryo .......................................... 11 
5. CRISPR/Cas9 ................................................................................................. 12 
III. Materials and Methods ................................................................................... 16 
1. Materials ......................................................................................................... 16 
1.1 Apparatuses .................................................................................................. 16 
1.2 Software ....................................................................................................... 17 
1.3 Consumables ................................................................................................ 18 
1.4 Chemicals , enzymes and other reagents...................................................... 19 
1.5 Oligonucleotides .......................................................................................... 22 
1.6 Antibodies .................................................................................................... 22 
1.7 Hormones ..................................................................................................... 22 
1.8 Media and Buffers ........................................................................................ 23 
1.8.1 Buffers .............................................................................................. 23 
1.8.2 Media for in vitro production of embryos ........................................ 24 
1.8.3 Media for embryo manipulation and fixation ................................... 27 
1.8.4 Media for cell culture ....................................................................... 28 
2. Methods .......................................................................................................... 29 
2.1 In vitro production of bovine embryos ........................................................ 29 
  
Table of contents   II 
2.2 Embryo manipulation ................................................................................... 29 
2.3 Zona pellucida removal................................................................................ 29 
2.4 Morula disaggregation ................................................................................. 30 
2.5 Chimera production ...................................................................................... 30 
2.5.1 Sandwich technique .......................................................................... 31 
2.5.2 Aggregation technique ..................................................................... 31 
2.6 Time lapse imaging ...................................................................................... 32 
2.7 Cell culture procedures ................................................................................ 32 
2.8 CRISPR/Cas9 mediated production of OCT4 knockout host embryos ....... 33 
2.8.1 CRISPR/Cas9 design ........................................................................ 33 
2.8.2 Transfection of adult fibroblasts ....................................................... 33 
2.8.3 Selection of single cell clones .......................................................... 34 
2.8.4 DNA isolation ................................................................................... 34 
2.8.5 Screening of single-cell clones ......................................................... 35 
2.9 Somatic cell nuclear transfer ........................................................................ 37 
2.10 Control embryos ......................................................................................... 37 
2.11 Albertini fixation of embryos ..................................................................... 37 
2.12 Imaging procedures .................................................................................... 38 
2.12.1 Imaging of chimeric embryos ....................................................... 38 
2.12.2 Immunofluorescent expression analysis ....................................... 38 
2.12.3 Confocal microscopy .................................................................... 39 
2.12.4 Image analysis............................................................................... 40 
2.13 Statistical analysis ...................................................................................... 40 
IV. Results ............................................................................................................ 41 
1. Chimeras with wild-type host embryos.......................................................... 41 
1.1 Host and donor embryo development ...................................................... 41 
  
Table of contents   III 
1.2 Chimera development and donor blastomere integration ........................ 41 
1.3 Cell numbers ............................................................................................ 43 
1.4 CLSM analysis of chimeras with wild-type hosts ................................... 44 
2. OCT4 knockout embryos ............................................................................... 46 
2.1 CRISPR/Cas9 targeting efficiency .......................................................... 46 
2.2 CRISPR/Cas9 off target effects ............................................................... 47 
2.3 Somatic cell nuclear transfer.................................................................... 48 
2.4 Immunofluorescence analysis .................................................................. 51 
2.4.1 OCT4 and CDX2 .............................................................................. 51 
2.4.2 NANOG and GATA6 ....................................................................... 53 
3. Chimeras with OCT4 KO host embryos ........................................................ 57 
V. Discussion .......................................................................................................... 60 
VI. Summary ........................................................................................................ 72 
VII. Zusammenfassung .......................................................................................... 74 
VIII. Index of Tables ............................................................................................... 76 
IX. Index of Figures ............................................................................................. 78 
X. References .......................................................................................................... 81 
XI. Acknowledgements ........................................................................................ 93 
 
 
 
 
 
 
  
Index of Abbreveations  IV 
INDEX OF ABBREVEATIONS 
BME Basal medium Eagle’s amino acids solution 
bp Basepairs 
CDX2 Caudal type homeobox 2 
CLSM Confocal laser scanning microscope 
COC Cumulus–oocyte complex 
CR4 Conserved region 4 
CRISPR Clustered regulatory interspaced palindromic 
repeats 
crRNA CRISPR RNA 
DAPI 4′,6-Diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
dNTP Nucleoside triphosphate 
DSB Double strand break  
DTT 1,4-dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EGA Embryonic genome activation  
eGFP Enhanced green fluorescent protein 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid tetrasodium salt 
EPI Epiblast 
ESC Embryonic stem cells 
ETF1 Eukaryotic translation termination factor 1 
FCS Fetal calf serum 
  
Index of Abbreveations  V 
FGF4 Fibroblast growth factor 4 
FGFR Fibroblast growth factor receptor 
FSH Follicle stimulating hormone 
GATA3 GATA binding protein 3 
GATA6 GATA binding protein 6 
GEBV Genomic estimated breeding value 
gRNA Guide RNA 
HB Hypoblast 
HDR Homology directed repair 
hep Heparin 
ICM Inner cell mass 
indel Insertion or deletion 
iPSC Induced pluripotent stem cells 
IVF In vitro fertilization 
IVM In vitro maturation 
IVP In vitro produced  
KO Knockout 
LH Luteinizing hormone 
MAPK Mitogen-activated protein kinase 
MEM Minimum essential medium 
MOET Multiple ovulation embryo transfer 
MSTN Myostatin 
NANOG Nanog homeobox 
NHEJ Non-homologous end-joining repair 
OCS Estrous cow serum 
  
Index of Abbreveations  VI 
OCT4 Octamer-binding transcription factor-4 
PAM Protospacer adjacent motif 
PBS Phosphate buffered saline  
PCR Polymerase chain reaction 
PE Primitive endoderm 
PGCs Primordial germ cells 
PHA Phytohemagglutinin-L  
PVA Polyvinyl alcohol 
RNA Ribonucleic acid 
SCNT Somatic cell nuclear transfer 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
sgRNA Small guiding RNA 
SNP Single nucleotide polymorphisms 
SOF Synthetic oviductal fluid 
Sox17 Sex determining region Y-box 17 
Sox7 Sex determining region Y-box 7 
TALEN Transcription activator-like effector nucleases 
TE Trophectoderm 
TL-HEPES-PVA HEPES-buffered Tyrode's medium with PVA 
tracrRNA Trans-activating RNA 
Tris Tris-(hydroxymethyl)-aminomethane 
WoW Well of the well 
ZFN Zinc-finger nucleases 
ZP Zona pellucida 
  
I. Introduction 1 
I. Introduction 
The advent of genomic selection using single nucleotide polymorphisms (SNP) 
revolutionized breeding schemes in cattle (HAYES et al., 2009). Provided that 
enough data on the phenotypes and genotypes of several generations is included, the 
genomic estimated breeding value (GEBV) even exceeds the traditional EBV in 
accuracy (MUIR, 2007), while simultaneously the generation interval and the costs 
of genetic progress are dramatically reduced (SCHAEFFER, 2006). The genotype of 
an individual is fixed at the time of fertilization, so the GEBV of an embryo is as 
valid as the GEBV from animals of any age (SEIDEL, 2009). This development may 
lead to individual embryos from multiple ovulation embryo transfer (MOET) or in 
vitro production with great commercial value due to a high GEBV. A biopsy of ~10 
cells, which is necessary to generate a GEBV, unfortunately compromises the 
embryo. This leads to decreased pregnancy rates after transfer to recipients, 
especially after cryopreservation (CENARIU et al., 2012; PONSART et al., 2014). 
Therefore, the multiplication of commercially valuable embryos is highly desired, 
mostly to ensure that a pregnancy with the promising genotype is established. 
Different multiplication strategies have been developed, including embryonic cell 
nuclear transfer (ZAKHARTCHENKO et al., 1995) and the production of 
monozygotic twins through blastomere separation (TAGAWA et al., 2008), but both 
methods have not been used commercially because of technically demanding 
protocols and low efficiencies, respectively.  
Alternatively, embryos may be multiplied by chimeric complementation, where a 
few pluripotent progenitor cells from a genetically valuable donor embryo are 
combined with host embryos to form the inner cell mass (ICM) and later give rise to 
the embryo proper, whereas host embryos preferentially contribute to the 
trophectoderm (TE) and thus form extraembryonic tissues. To exclude host embryos 
from the ICM, they are e.g. manipulated by electrofusion at the two-cell stage 
(HIRIART et al., 2013). Still, host embryos that are definitely not able to contribute 
to the ICM and therefore guarantee non-chimeric offspring with the desired genotype 
are not available.  
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One objective of this thesis was to develop an embryo multiplication method using 
chimeric complementation with host embryos that do not contribute to the ICM. To 
achieve that, first an aggregation technique with wild-type host embryos was 
established, which reliably generated transferable blastocysts from the chimeric 
constructs. Second, genetically modified host embryos that are unable to maintain a 
pluripotent state and therefore cannot contribute to the embryo proper, were 
produced by knockout (KO) of the pluripotency regulating transcription factor OCT4 
(POU5F1). At the same time, this is the first knockout study to investigate the 
function of OCT4 in bovine preimplantation embryos, so additionally this thesis sets 
out to describe the phenotype of bovine OCT4 KO embryos and the effect of an 
OCT4 KO during the first and the second lineage differentiation.   
Parts of this dissertation have been published and were presented at conferences: 
Simmet K, Reichenbach M, Reichenbach H-D, Wolf E. Phytohemagglutinin 
facilitates the aggregation of blastomere pairs from Day 5 donor embryos 
with Day 4 host embryos for chimeric bovine embryo multiplication. 
Theriogenology 2015a; 84: 1603-10. 
 
Simmet K, Reichenbach M, Jung S, Fries R, Grupp T, Gschoederer C, Scherzer J, 
Reichenbach H, Wolf E (2015b) Phytohemagglutinin (PHA) influences 
blastocyst rate and contribution of donor cells to the inner cell mass of 
asynchronous bovine embryo aggregation chimeras. Reproduction in 
Domestic Animals. 16- 
 
Simmet K, Reichenbach M, Jung S, Fries R, Grupp T, Gschöderer C, Scherzer J, 
Reichenbach H, Wolf E (2015c) 84 Pairs of blastomeres from bovine day 5 
morulae are able to contribute to inner cell mass and trophectoderm in 
chimeric embryos generated by aggregation with two day 4 morulae. 
Reproduction, Fertility and Development. 135- 
 
Simmet K, Klymiuk, N., Zakhartchenko, V., Güngör, T., Reichenbach, M., 
Reichenbach, H.D., & Wolf, E. (2016) OCT4 (POU5F1) has no influence on 
the ratio of inner cell mass to trophectodermal cells in cloned bovine day 7 
blastocysts. In: 18th International Congress on Animal Reproduction, ICAR 
2016, Tours, France 
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II. Review of Literature 
1. Chimeric embryos 
By definition, a chimera is an organism composed from two or more different 
zygotic cell lines (ANDERSON et al., 1951). In contrast, mosaicism is the presence 
of genetically distinct cell lines in one organism, which derived from one single 
zygote (COTTERMAN, 1956).  
There are several forms of naturally occurring chimerism. Blood chimerism occurs 
when dizygotic twins share common blood vessels during their development in utero 
or fetal-maternal blood interchange develops, so hematopoietic stem cells seed 
mutually in the twins or in the fetus and mother, resulting in a chimeric 
hematopoietic system. Dispermic chimerism is the aggregation result of two or more 
different zygotes, which grow into one single body. Several case studies on this rare 
condition have been reported in humans, which are usually detected by sexual 
abnormalities (SAWAI et al., 1994; REPAS-HUMPE et al., 1999; RINKEVICH, 
2001). A germ line chimera, or germ line parasitism, develops, when the primordial 
germ cells (PGCs) of one organism reach the gonads of another and colonize them, 
so germ cells later stem from a different organism (RINKEVICH, 2001), which was 
already observed in cattle (OHNO et al., 1962).  
The first chimeric embryo produced by manipulation was reported by TARKOWSKI 
(1961), who joined two 8-cell mouse embryos and transferred developed blastocysts 
to recipients, resulting in live offspring. Since then, embryonic chimeras served as 
useful tools to study the early development and cell differentiation in mammalian 
embryos. For instance, several studies used mouse chimeras to investigate the 
totipotency of distinct cell populations in morulae (inside and outside cells) at 
different time points of development, concluding that up to the 32-cell stage, all cells 
can still differentiate into all three cell lineages and are therefore totipotent 
(SUWIŃSKA et al., 2008; TARKOWSKI et al., 2010). Also the degree of 
differentiation in bovine trophectodermal cells was examined, which are surprisingly 
still able to contribute to the ICM of a chimeric blastocyst and thus are capable of 
changing their cell fate in a new environment (BERG et al., 2011).  
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The complementation of a tetraploid blastocyst with pluripotent cells gives 
irrefutable proof of pluripotency, if the added cells contribute to the three germ cell 
layers and to the germ line cells. A tetraploid blastocyst is produced by electro-fusion 
at the two-cell stage, addition of a diploid nucleus to a zygote or inhibition of 
cytokinesis before the first cleavage (EAKIN & BEHRINGER, 2003). In species, 
where embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) exist, 
chimeric complementation is also used to produce genetically modified animals. The 
pluripotent cells are modified, e.g. by gene targeting, and then injected into a 
tetraploid blastocyst where they colonize the ICM, which results in chimeric 
offspring. If the genetically modified cells also develop into germ line cells, the 
chimeric animals can produce offspring carrying the desired modification (NAGY et 
al., 1990; PASCOE et al., 1992; KANG et al., 2009; ZHAO et al., 2009).   
The first bovine chimeras were produced by injection of ICM cells to day 7 
blastocysts, by aggregation of day 5 morulae and by microsurgical combination of 
half day 5 embryos (up to four halves) within an empty zona pellucida (ZP). Both 
techniques resulted in live chimeric offspring, amongst others documented by 
chimeric coat colors, as shown in Figure 1 (SUMMERS et al., 1983; BREM et al., 
1984). 
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Figure 1: Chimeric calf from microsurgical combination of half day 5 embryos. Adapted 
from BREM et al. (1984). 
Subsequently, ICMs from different developmental stages (day 8, 10 or 14) were 
aggregated with day 5.5 morulae, but only ICMs from day 8 and 10 blastocysts were 
able to contribute to chimeric embryos and additionally live chimeric calves were 
exclusively born from chimeric embryos with ICMs from day 8. The authors 
concluded, that aggregation partners cannot overcome a developmental gap of more 
than 3 days (PICARD et al., 1990). To test the possibility of producing transgenic 
animals via chimeric complementation of pluripotent transgenic cells with embryos, 
bovine ES-like cells were microinjected with DNA or ES-like cells were derived 
from ICMs of embryos reconstructed from transgenic fibroblasts via somatic cell 
nuclear transfer (SCNT). Day 3 morulae were injected with these pluripotent 
transgenic cells and live calves were born from both approaches, showing transgene 
integration in at least one tissue including the gonadal tissue in one calf. 
Nevertheless, a low transfection efficiency and poor developmental rates of embryos 
prevented further use of this approach (CIBELLI et al., 1998). Also, aggregation of 
ES-like cells with tetraploid 8-cell embryos produced by electrofusion at the two-cell 
stage could not increase the efficiency in production of live chimeric offspring 
(IWASAKI et al., 2000). 
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2. Multiplication of embryos through chimeric complementation 
When embryonic chimeras are produced with the intention to promote a certain 
lineage in the offspring, e.g. a transgenic or a desired genotype, measures are taken 
to drive a host embryo to differentiation towards the extraembryonic tissues. 
Simultaneously, these strategies increase the colonization of the ICM by a donor 
embryo or pluripotent cells, so a greater proportion of the embryo proper emerges 
from the desired genotype. Multiplication of elite embryos by the production of 
aggregation chimeras is based on the concept, that few blastomeres of a donor 
embryo form the ICM, whereas host embryo cells preferentially contribute to the TE 
during the first lineage differentiation to support development of the donor. Thereby 
several chimeras, that later contain cells from the elite embryo in the ICM, may be 
produced from a single donor embryo. This helps to ensure pregnancy with an elite 
genotype and to multiply offspring of a single mating.   
Differentiation of the host embryo to TE may be achieved by asynchronous 
aggregation or use of host embryos with chromosomal aberrations. In asynchronous 
aggregation, the developmentally more advanced aggregation partner is prone to 
contribute to the ICM, excluding the host embryo from the pluripotent lineage. 
Calves from aggregation of a day 8 ICM and a day 5.5 morula predominantly 
showed the phenotype of the ICM (PICARD et al., 1990). Also, aggregation of a 
single eGFP positive blastomere from a day 3 embryo with either synchronous (day 
3) or asynchronous (day 2) host embryos resulted in 0% integration of the donor 
blastomere to the ICM in synchronous aggregation vs. 22% in the asynchronous 
aggregation (HIRIART et al., 2013). In the mouse, it is state of the art to use 
tetraploid host embryos, i.e. embryos with chromosomal aberrations. Such embryos, 
produced by electro-fusion at the two-cell stage, show a uniformly tetraploid 
karyotype (EAKIN & BEHRINGER, 2003) and viable mice completely derived from 
ESCs may be obtained after chimeric aggregation (NAGY et al., 1993). This is based 
on the principle that blastomeres with an abnormal karyotype are preferentially 
allocated in the TE (IWASAKI et al., 1992; NAGY et al., 1993; VIUFF et al., 2002). 
Production of tetraploid embryos in the bovine is less successful regarding uniform 
tetraploidy and complementation with ES-like cells (IWASAKI et al., 1989; 
CURNOW et al., 2000; IWASAKI et al., 2000) and it has been reported, that 
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embryos fused at the two-cell stage even contain a higher number of diploid 
blastomeres than non-fused ones. This particular study also did not detect any 
significant differences between chimeras with fused or non-fused hosts regarding 
integration of the donor cell to the ICM or the overall blastocyst (HIRIART et al., 
2013). Preimplantation embryos with chromosomal aberrations can be identified 
using their developmental kinetics. Several parameters, such as timing of first and 
second cleavage, have been determined to select the developmentally most 
competent embryos produced in vitro. In turn, those thresholds can also be used to 
obtain host embryos containing a high percentage of blastomeres with an abnormal 
karyotype. Embryos that do not complete their first cleavage until 27 h after 
fertilization show a dramatically decreased development to diploid blastocysts 
(Figure 2), which defines this time point as a suitable cut-off to select for embryos 
with an abnormal karyotype (SUGIMURA et al., 2012). 
 
Figure 2: Relationship between timing of the first cleavage and the incidence of diploid 
embryos. Blastocysts were divided into two groups, fast and slow, based on the timing of the 
first cleavage with a cut-off of 27 hpi. Adapted from SUGIMURA et al. (2012).  
A bovine chimeric embryo whose ICM solely contains cells derived from a donor 
embryo or a different source of pluripotent cells has not been reported yet, as the 
current strategies still fail to exclude the host from pluripotent lineages.  
3. Use of phytohemagglutinin-L for embryo aggregation 
Phytohemagglutinin-L (PHA) is the leukocyte specific subunit of a lectin produced 
from Phaseolus vulgaris (red kidney bean). It is a glycoprotein that binds to cellular 
surfaces by means of specific glycol conjugates and it has mitogenic and 
agglutinating properties (MINTZ et al., 1973; MALLIKARJUNAN et al., 2014). 
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When added to in vitro maturation medium of bovine oocytes or to embryo culture 
medium, it has no effect on embryonic development in low concentrations (WANG 
et al., 2001), but concentrations exceeding 300 µg/ml are detrimental (DU et al., 
2006). The agent was also used in the SCNT procedure, where treatment of 
enucleated oocytes with PHA increased the fusion rate and overall efficiency or 
enabled performing the SCNT procedure without ZP or the use of a 
micromanipulation unit (VAJTA et al., 2001; OBACK et al., 2003; DU et al., 2006). 
PHA is a carbohydrate binding protein and therefore suitable to aggregate embryos, 
because embryos treated with PHA stick together and form stable constructs. First 
aggregation experiments were performed with mouse embryos, where firm and quick 
adhesion between aggregation partners already after short exposure was reported, 
which remained stable in PHA-free culture medium (MINTZ et al., 1973). With the 
aim to increase the efficiency of bovine SCNT, PHA was also successfully used to 
aggregate bovine embryos (MISICA-TURNER et al., 2007; AKAGI et al., 2011). To 
avoid uncontrolled aggregation after treatment with PHA, the constructs can be 
cultured in a well of the well (WoW) culture dish, which allows individual culture of 
aggregates while maintaining positive group culture effects (PALMA et al., 1992; 
VAJTA et al., 2000; FUJITA et al., 2006).  
4. The pluripotency regulating transcription factor OCT4  
The gene OCT4 (POU5F1) encodes the octamer-binding transcription factor-4 
(OCT4), which belongs to the pit-oct-unc (POU) family of transcription factors. It 
regulates the expression of candidate genes by binding through helix-turn-helix to an 
octamer sequence motif (ATGCAAAT) in their promoter and/or enhancer regions 
(SCHÖLER, 1991; HERR & CLEARY, 1995). OCT4 is linked to the pluripotent 
properties of blastomeres, ESCs and iPSCs, where it maintains, induces and regulates 
pluripotency (WANG & DAI, 2010; WU & SCHÖLER, 2014). It is also required for 
the establishment of primordial germ cells (KEHLER et al., 2004). The OCT4 
protein is highly conserved between species and mouse, human and bovine OCT4 are 
true orthologs with the bovine OCT4 sharing 90.6% and 81.7% identity with human 
and mouse OCT4, respectively (VAN EIJK et al., 1999).   
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4.1 Oct4 in the preimplantation mouse embryo 
In mouse embryos, the OCT4 protein is already found in oocytes and later it is 
located in all nuclei until blastocyst stage, when it is restricted to the nuclei in the 
ICM (PALMIERI et al., 1994). Exclusive expression of OCT4 in the ICM is 
established through downregulation of OCT4 in the TE by the TE-specific 
transcription factor CDX2 (NIWA et al., 2005; RALSTON & ROSSANT, 2008). It 
is now established, that Oct4 is at the top of the pluripotency regulatory hierarchy 
(WU & SCHÖLER, 2014), although it is neither necessary for the first lineage 
segregation into ICM and TE nor for the initiation of toti- or pluripotency 
(NICHOLS et al., 1998; FRUM et al., 2013; WU et al., 2013).  
These findings are based on KO studies, with the first being performed by NICHOLS 
et al. (1998), who found that Oct4 KO mouse embryos develop until blastocyst stage, 
but without a pluripotent ICM and that the mutation results in peri-implantation 
lethality. Furthermore, the authors revealed that in the absence of OCT4, 
proliferation of the TE was not maintained, due to the missing fibroblast growth 
factor 4 (FGF4), which is a target gene of OCT4. Using a Cre/loxP recombinase 
system, it was possible to induce an Oct4 KO in both the maturing oocytes and 
resulting zygotes. In short, Cre expression was driven from the Zp3 promoter to 
induce recombination in the primary follicles’ oocytes in females with a 
heterozygously floxed Oct4. Mating with heterozygous males resulted in progeny 
deficient of maternal and zygotic OCT4 at Mendelian frequencies. Studies 
employing this system found, that the establishment of totipotency is not OCT4 
dependent, as embryos showed normal development until blastocyst stage (FRUM et 
al., 2013; WU et al., 2013; LE BIN et al., 2014). The first lineage differentiation in 
the embryo, when TE and ICM segregate, is not compromised by an Oct4 KO. At 
day 3.5 (the late blastocyst stage), Oct4 KO embryos exhibit normal cell numbers in 
the TE and ICM and also expression of GATA3 and CDX2, factors that induce 
differentiation of the TE, are repressed in the ICM (NICHOLS et al., 1998; 
RALSTON et al., 2010; WU et al., 2013).  
The second lineage differentiation begins at the late blastocyst stage, when epiblast 
(EPI) and primitive endoderm (PE) segregate within the ICM. Precursor cells already 
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express lineage specific marker genes, resulting in a salt and pepper distribution of 
NANOG and GATA6 positive blastomeres, which later form EPI and PE by day 
3.75, respectively (CHAZAUD & YAMANAKA, 2016). Embryos deficient of 
OCT4 also exhibit a mutually exclusive expression of NANOG and GATA6 at day 
3.75. With ongoing development, GATA6 positive cells disappear from the ICM and 
the proportion of cells neither expressing GATA6 nor NANOG (unlabeled cells) 
increases until day 4.25, when almost no GATA6 positive cells are found. Activation 
of PE specific gene expression, i.e. Gata6, Sox17 and Sox7, fails and thus there is no 
development of PE (FRUM et al., 2013; LE BIN et al., 2014).  
In mouse embryos, expression of PE genes can be induced by addition of exogenous 
FGF4 and heparin (FGF4/hep) to the culture medium, with the result that all cells of 
the ICM will express GATA6 (YAMANAKA et al., 2010). Additionally, embryos 
lacking FGF4 have an ICM entirely made up of NANOG positive cells (KANG et 
al., 2013) and the same is also true for embryos treated with FGFR/MAPK signaling 
inhibitors (LANNER & ROSSANT, 2010). Fgf4 is a target gene of OCT4 and Fgf4 
mRNA levels in Oct4 KO embryos are reduced (NICHOLS et al., 1998). Treatment 
of Oct4 KO embryos with FGF4/hep cannot activate PE gene expression or repress 
NANOG expression, leading to the conclusion that OCT4 is required for exogenous 
FGF4 to act upon cells in the ICM. In chimeras from an Oct4 KO embryo and wild-
type ESCs, the ESCs are not able to rescue PE development, so OCT4 is required 
cell-autonomously for PE differentiation (FRUM et al., 2013; LE BIN et al., 2014). 
In summary, the current working model (Figure 3) states, that in EPI cells OCT4 
regulates the expression of FGF4, which induces PE cell fate and that additionally, 
OCT4 in the PE cells activates the expression of PE genes (FRUM et al., 2013).        
  
II. Review of Literature 11 
 
Figure 3: Working model of OCT4 during the second lineage differentiation. Adapted from 
FRUM et al. (2013). 
4.2 OCT4 in the preimplantation bovine embryo 
Bovine embryos develop to early blastocysts at day 6-7 and segregation of EPI and 
hypoblast (HB, the equivalent to the PE in mouse) in the ICM occurs around day 8 
(MADDOX-HYTTEL et al., 2003), while implantation begins at  day 16-18 
(HYTTEL et al., 2009). Mouse embryos develop at a faster pace, reaching 
implantation already at day 4.5 (NAGY et al., 2003). Similar to mouse embryos, 
maternal OCT4 transcripts are already detected in the oocyte and decrease until the 
8-16 cell stage, when embryonic genome activation (EGA) occurs. After EGA, 
OCT4 is detected in all nuclei of the morula (KIRCHHOF et al., 2000; KUROSAKA 
et al., 2004; WUENSCH et al., 2007). While the canonical lineage marker CDX2 
extinguishes OCT4 expression in the TE of day 3.5 late mouse blastocysts, bovine 
embryos co-express CDX2 and OCT4 in the TE until day 11. Mouse CDX2 is able to 
shut down OCT4 expression due to the conserved region 4 (CR4) in the Oct4 locus, 
which differs from the bovine and human CR4. When the mouse CR4 is exchanged 
with the bovine, CDX2 no longer extinguishes OCT4 expression in mouse TE. This 
difference in mouse preimplantation development to other species allows rapid 
differentiation of the TE and implantation of the embryo (NORDHOFF et al., 2001; 
BERG et al., 2011).  
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At day 8, the same salt and pepper distribution of GATA6 and NANOG positive 
cells is present in the bovine ICM when compared to the mouse. Nevertheless, the 
role of FGF4 is not analog to the situation in the mouse: inhibition of MAPK, FGFR 
or FGF4 signaling only partially blocks GATA6 expression and therefore HB 
development in the bovine embryo, while addition of FGF4/hep leads to GATA6 
expression in all ICM cells. Therefore, FGF signaling is not required for normal 
GATA6 expression and the effect of exogenous FGF4 on GATA6 expression is 
indirect in bovine embryos (KUIJK et al., 2012).  
At the time of writing this review, no knockout study but two knockdown studies of 
OCT4 had been performed in bovine embryos, which used RNA interference to 
suppress transcription of OCT4. NGANVONGPANIT et al. (2006) reported 
successful reduction of OCT4 transcript abundance by 72% at blastocyst stage, but 
development to day 5 morulae or total blastocyst rate remained unchanged. 
Reduction of OCT4 concomitantly reduced the level of FGF4 transcripts, showing 
that - like in mouse - FGF4 is regulated by OCT4. The authors also recorded a 
reduced cell number in the ICM of OCT4 knockdown blastocysts, while the number 
of TE cells did not differ. More recently, SAKURAI et al. (2016) followed the same 
methodological approach and confirmed the dependence of FGF4 on OCT4. 
Nevertheless, they recorded a reduced blastocyst rate and OCT4 knockdown day 7 
blastocysts had only half as much total cells as controls. Existing data on the function 
of OCT4 in bovine embryos is scarce and in part contradicting. Additionally, 
differences in OCT4-CDX2 interaction and in regulation of GATA6 expression 
through FGF4 signaling between bovine and mouse suggest, that the underlying 
mechanisms involving OCT4 are not the same and that the model organism mouse 
does not entirely reflect the early developmental events in bovine embryos. 
Therefore, it is necessary to study the role of OCT4 in bovine embryos with a 
definitive knockout.  
5. CRISPR/Cas9  
Genome editing tools, i.e. zinc-finger nucleases (ZFN), transcription activator-like 
effector nucleases (TALEN) and Cas9 endonuclease associated to clustered 
regulatory interspaced palindromic repeats (CRISPR/Cas9), enable researchers to 
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manipulate any gene in a broad range of organisms. These tools are capable of 
inducing a double strand break (DSB) at a defined location, which leads to DNA 
repair mechanisms, amongst others non-homologous end-joining repair (NHEJ) and 
homology directed repair (HDR). The error prone NHEJ eventually leads to 
insertions or deletions (indels) of nucleotides, while through HDR a perfect repair of 
the DSB or targeted insertion of an exogenous repair template may be achieved (GAJ 
et al., 2013). The CRISPR/Cas9 system is derived from an ancient bacterial defense 
mechanism, where CRISPRs represent the memory from previous infections and the 
Cas9 endonuclease the effector inducing the DSB in foreign DNA (SERUGGIA & 
MONTOLIU, 2014). In bacteria, the CRISPRs are processed into CRISPR RNAs 
(crRNAs), which bind to trans-activating RNAs (tracrRNA) to form a complex with 
Cas9. To use CRISPR/Cas9 as a genome editing tool, the fusion product of the 
crRNA and tracrRNA (gRNA) is introduced to a cell or organism together with 
Cas9. 20 customizable nucleotides at the 5’ end of the gRNA, the small guiding 
RNA (sgRNA), then direct Cas9 to a specific site through Watson&Crick base 
pairing, where Cas9 finally induces a DSB. The only limitation in designing the 
sgRNA is the obligatory presence of a NGG protospacer adjacent motif (PAM) at its 
3’ end, which on average occurs every 8 bp in the mammalian genome (SANDER & 
JOUNG, 2014; SERUGGIA & MONTOLIU, 2014). In comparison with ZFNs and 
TALENs, CRISPR/Cas9 is easier to design, has a higher mutagenesis efficiency and 
is inexpensive (SERUGGIA & MONTOLIU, 2014). Also, it enables simultaneous 
multiplex editing of several genes (HSU et al., 2014).  
The first application report of CRISPR/Cas9 in mammalian embryos was published 
by WANG et al. (2013), who simultaneously disrupted five genes in mouse ESCs, 
which can be used to produce offspring with germline transmission. They also 
generated mice with a biallelic knockout of two genes by injection of CRISPR/Cas9 
to the cytoplasm of zygotes, which allowed the production of mutant mice in only 
one step with a very high efficiency of 80%. Subsequently, this approach was 
repeated targeting a single gene in pig zygotes, which resulted in 37.5% of the 
offspring carrying a biallelic mutation (HAI et al., 2014). Bovine zygotes and iPSCs 
were also targeted with CRISPR/Cas9 to achieve a gene knockin with an efficiency 
of 14% in blastocysts and 100% in picked colonies (HEO et al., 2014). In sheep, KO 
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of the myostatin gene (MSTN), a desired mutation in livestock species, was achieved 
by injection of CRISPR/Cas9 to zygotes, with 36.4% of the offspring carrying a 
biallelic mutation (CRISPO et al., 2015). A disadvantage in generation of genome-
edited animals through injection of CRISPR/Cas9 at the zygote stage is the 
occurrence of mosaicism in the offspring. A study that targeted the Tyr locus in 
mouse zygotes (a knockout results in complete albinism) reports, that from 33 pups 
one complete albino and three pigmentation mosaics were generated while the rest 
was fully pigmented. Deep sequencing also showed, that the majority of the mutated 
pups had more than two new mutant alleles (YEN et al., 2014). Also in pig, mosaic 
offspring has been reported after zygote injection (WHITWORTH et al., 2014) and 
at a high frequency of 80% also in sheep (CRISPO et al., 2015). Somatic mosaicism 
and allele complexity may complicate subsequent work, especially when the 
mosaicism also affects the germline (YEN et al., 2014). A common strategy to 
produce genetically modified animals, mainly in species where ESCs don’t exist, is 
to target somatic cells and reconstruct embryos via SCNT. With this approach, 
mosaicism is unlikely to occur and the exact mutation is known before transfer of 
embryos to recipients. With this strategy, goats with a MSTN KO and pigs with a KO 
of CD163 and CD1D were successfully produced (NI et al., 2014; WHITWORTH et 
al., 2014). Bovine fibroblasts were also transfected to produce a knockin of human 
FGF2 at the -casein gene locus with subsequent embryo production through SCNT 
(JEONG et al., 2016), but still there is no report on bovine CRISPR/Cas9 genome-
edited offspring, neither through zygote injection nor SCNT.  
CRISPR/Cas9 technology bares great possibilities for the study of preimplantation 
embryonic development, because the function of genes may be easily determined, 
e.g. by performing KO or knockin of a reporter construct. Using these new strategies, 
i.e. injection at the zygote stage or reconstruction with modified somatic cells, 
investigators are now able to verify, if mechanisms established in the mouse model 
proof true for other mammalian species. A first report is available in the pig, where a 
OCT4 KO was successfully induced by CRISPR/Cas9 injection at the zygote stage 
(KWON et al., 2014) and in the United Kingdom, researches gained the permit to 
investigate the role of OCT4 in human embryos using CRISPR/Cas9 (CALLAWAY, 
2016).  
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The aims of this thesis were i) to study the feasibility of multiplying selected bovine 
embryos by aggregation with host embryos and ii) to investigate the role of OCT4 in 
bovine preimplantation embryos including the implications on the second lineage 
differentiation. 
Multiplication of selected embryos was studied by aggregating pairs of blastomeres 
from day 5 morulae with two day 4 host embryos, which did not complete their first 
cleavage until 27 h after in vitro fertilization (IVF). Also, the effect of PHA on 
chimera formation and position of the donor cells in the chimeric blastocysts was 
investigated.  
To investigate the role of OCT4, a KO model was established, which allowed the 
production of OCT4 KO embryos with SCNT using mutated donor nuclei. The OCT4 
KO phenotype was then analyzed by immunofluorescence staining of the markers of 
all three lineages in the preimplantation embryo, i.e. CDX2, GATA6 and NANOG 
for the TE, HB and EPI, respectively. With data from confocal laser scanning 
microscopy (CLSM), it was possible to thoroughly analyze the impact of OCT4 
deficiency on embryonic development. 
Additionally, aggregation of wild-type embryos with embryos lacking a pluripotent 
lineage (OCT4 KO embryos) was performed to test the biotechnological use of 
OCT4 KO embryos in multiplication of elite embryos and to investigate, if few wild-
type blastomeres can rescue the lethal OCT4 KO phenotype. 
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III. Materials and Methods 
1. Materials  
1.1 Apparatuses 
170-300 incubator MMM Group, Munich 
5µl Transferpettor glass pipet Brand, Wertheim 
5415 D centrifuge  Eppendorf, Hamburg 
5417 R centrifuge  Eppendorf, Hamburg 
5810 R centrifuge  Eppendorf, Hamburg 
9040-0071 incubator Binder, Tuttlingen 
Accu-jet® pro pipette controller Brand, Wertheim 
Agarose gel electrophoresis chamber WG - Biotech, Ebersberg 
and OWL Inc., USA 
Axiovert 200 M epifluorescence microscope  Zeiss, Oberkochen 
Biofuge pico centrifuge Heraeus, Osterode 
Cellavista  SynenTec, Münster 
CO2Cell incubator MMM Group, Munich 
CoolCell BioCision, USA 
EASYpure® II pure aqua, Schnaitsee 
EBA 8S centrifuge Hettich, Tuttlingen 
Gel documentation system BioRad, Munich 
Geneamp PCR System 9700 thermocycler Applied Biosystems, 
USA 
GeneQuant Pro spectrophotometer Thermo Scientific, 
Schwerten 
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HAT 200 warming plate and heated microscope stage  Minitube, Tiefenbach 
Labcycler thermocycler SensoQuest, Göttingen 
Laminar flow HB 2448K Heraeus, Hanau  
Laminar flow HeraSafe HS12 Kendro, Hanau  
Laminar flow HV228 K Systems, Denmark 
LSM 710 confocal laser scanning microscope Zeiss, Oberkochen 
Microwave DAEWOO, Korea 
MS 5 Stereomicroscope Leica, Wetzlar 
Neubauer counting chamber Hecht Assistent, 
Sondheim vor der Rhön 
Nucleofector
TM
 II Lonza, Switzerland 
Pipettes (1000 µl, 200 µl, 10 µl) Brand, Wertheim 
Pipettes (1000 µl, 200 µl, 100 µl, 20 µl, 10 µl, 2.5 µl) Eppendorf, Hamburg 
Pipettes (1000 µl, 200 µl, 20 µl, 2 µl) Gilson Inc, USA 
Power Pac 300 gel electrophoresis unit BioRad, Munich 
Power Station 300 gel electrophoresis unit Labnet International, 
USA  
Rotanda 96 centrifuge Hettich, Tuttlingen 
Select vortexer Select BioProducts, USA 
Spectrafuge 24 D centrifuge Labnet International, 
USA  
SZ11 stereomicroscope  Olympus, Japan 
1.2 Software 
AxioVision V 4.9.1.0 Zeiss, Oberkochen 
Bio Edit Sequence Alignment Editor Tom Hall, USA 
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Fiji image J distribution National Institutes of 
Health, USA 
Finch TV Version 1.3.1 Geospiza Inc., USA 
Icy 1.6.0.0 Institut Pasteur, France 
Microsoft Office Suite Microsoft, USA 
Prism 5.02 for Windows GraphPad Software,  
USA 
Zen 2012 SP1 (black edition) Zeiss, Oberkochen 
1.3 Consumables 
 0.22 µm sterile filter Merck Millipore, 
Darmstadt 
100 mm culture dish Sarstedt, Nümbrecht 
Primovision embryo culture dish Vitrolife,  Sweden 
24-well culture plate Nunclon delta surface, 
USA 
30 mm cell culture dish Nunc, Braunschweig 
48-well culture plate Nunclon delta surface, 
USA 
4-Well culture plate  Nunc, Braunschweig 
60 mm culture dish Sarstedt, Nümbrecht 
6-well culture plate Cellstar Greiner Bio 
One, Frickenhausen 
96-well culture plate Nunclon delta surface, 
USA 
96-well half area 3696 culture plate Corning Costar, USA 
Centrifuge tubes (10 ml)  Nunc, Braunschweig 
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Centrifuge tubes (15 ml, 50 ml) Falcon, Becton 
Dickinson, Heidelberg 
Coverslips (26 x 21 mm, 0.17 ± 0.01 mm) Hecht Assistent, 
Sondheim vor der Rhön 
Coverslips (76 x 26 mm, 0.17 ± 0.01 mm) Hecht Assistent, 
Sondheim vor der Rhön 
Cryo vial (0.5 ml, 1.5 ml) TPP, Switzerland 
Glass pasteur pipettes Brand, Wertheim 
PCR reaction tubes (0.2 ml) Brand, Wertheim 
Perforated adhesive-backed PVC-film  Mactac, USA 
Pipet tips with filter (10 µl, 20 µl, 200 µl, 1000 µl) Kisker Biotech, Steinfurt 
Pipette tips (250 μl, 1000 μl)  Eppendorf, Hamburg 
Safe-Lock  reaction tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf, Hamburg 
Sperm, sire Mirsanmir Bayern Genetik, Grub 
1.4 Chemicals , enzymes and other reagents 
1,4-Dithiothreitol (DTT) Sigma, Steinheim 
2-Mercaptoethanol Roth, Karlsruhe 
Albumin, from bovine serum  Sigma, Steinheim 
Amaxa
TM 
Basic Nucleofector
TM 
Kit Primary Fibroblasts  Lonza, Switzerland 
Aprotinin from bovine lung  Sigma, Steinheim 
BigDye® Terminator v3.1 Applied Biosystems, 
Weiterstadt 
BME amino acids solution  Sigma, Steinheim 
Bromophenolblue Merck, Darmstadt 
CaCl2H2O Sigma, Steinheim 
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Chloroform (Trichloromethane) Roth, Karlsruhe 
Deuteriumoxid  Fisher Scientific, USA 
Donkey serum Jackson Immuno 
Research, United 
Kingdom 
dNTPs (dATP, dCTP, dGTP, dTTP) Thermo Scientific, 
Schwerte 
EDTA (Ethylenediaminetetraacetic acid) Roth, Karlsruhe  
EGTA (Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid tetrasodium salt) 
Sigma, Steinheim 
Ethanol Roth, Karlsruhe 
Ethidiumbromide (1mg/mL) Merck, Darmstadt  
Fetal calf serum Invitrogen, Karlsruhe 
Gene Ruler
TM 
1 kb Thermo Scientific, 
Schwerte 
Glycerin (Glycerol) Roth, Karlsruhe 
Heparin  Sigma, Steinheim 
HEPES Sigma, Steinheim 
Herculase II Fusion DNA Polymerase Agilant technologies, 
USA 
Herculase II 5x reaction buffer Agilant technologies, 
USA 
Isopropanol Roth, Karlsruhe 
KCl Sigma, Steinheim 
MEM Non-essential amino acid solution  Sigma, Steinheim 
Mg2Cl2H2O Sigma, Steinheim 
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MgCl2 Fluka Chemie, 
Switzerland 
Na lactate sirup (60%) Sigma, Steinheim 
NaCl Sigma, Steinheim 
NaH2PO2H2O Sigma, Steinheim 
NaH2PO4H2O  Sigma, Steinheim 
NaHCO3 Sigma, Steinheim 
Estrous cow serum (OCS) In house production 
Paraformaldehyde Sigma, Steinheim 
Phenol red Sigma, Steinheim 
Phytohaemagglutinin (PHA) Sigma, Steinheim 
Pipes  Sigma, Steinheim 
Polyvinylalcohol (PVA)  Sigma, Steinheim 
Pronase Sigma, Steinheim 
Proteinase K, ready to use Dako, Hamburg 
Pyruvic acid  Sigma, Steinheim 
SDS (Sodium dodecyl sulfate)  Serva Electrophoresis, 
Heidelberg  
Sodium acetate Sigma, Steinheim 
Taxol  Sigma, Steinheim 
Tris (Tris-(hydroxymethyl)-aminomethane) Roth, Karlsruhe 
Triton X-100 Sigma, Steinheim 
Universal Agarose Bio&SELL, Nürnberg 
Vectashield with DAPI Vector Laboratrories, 
 USA 
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1.5 Oligonucleotides 
OCT4 2f  5‘-TTGTGGGACCTTCAAAGTAATC-3‘ 
OCT4 2r  5‘-CTGCAGATTCTCGTTGTTGT-3‘ 
OCT4 12f  5‘-TATGTTCTTACATATCCTCTGC-3‘ 
OCT4 11f  5‘-CTCTTTGGTGAGTCTCCTACAG-3‘ 
ETF1 2f 5‘-TTGGGTGTGAAGTGGGTTTG-3‘ 
ETF1 2r 5’-CTGGGCGATGTGGCTAATTT-3’ 
ETF1 3f 5’-CTATGACTTGTGTGGAGGGATG-3’ 
boOCT4 sgRNA  5‘-GATCACACTAGGATATACCCAGG-3‘ 
1.6 Antibodies 
Rabbit anti-human NANOG 500-P236 Peprotech, Hamburg 
Goat anti-human GATA6 AF1700 R&D Systems, USA 
Rabbit anti-human CDX2 ab88129 Abcam, United Kingdom 
Goat anti-human OCT4 SC8628 Santa Cruz 
Biotechnology, USA 
Donkey anti-rabbit Alexa Fluor 555 ab150074 Abcam, United Kingdom 
Donkey anti-goat Alexa Fluor 633 A212082 ThermoFisher, USA 
1.7 Hormones 
Follicle stimulating Hormone (FSH) 50 Units Sioux Biochemical, USA 
Luteinizing Hormone (LH) 25 Units  Sioux Biochemical, USA 
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1.8 Media and Buffers 
1.8.1 Buffers 
Water deionized in a Millipore device (EASYpure® II) was used as solvent.  
Phosphate buffered saline (PBS)   
NaCl 8 mg/ml 
KCl 0.2 mg/ml 
KH2PO4 0.2 mg/ml 
NaH2PO4 · H2O 1.15 mg/ml 
MgCl2 · H2O 0.1 mg/ml 
CaCl2 0.1 mg/ml 
PBS without MgCl2 and CaCl2 (PBS w/o Mg
2+
, Ca
2+
) 
NaCl 8 mg/ml 
KCl 0.2 mg/ml 
KH2PO4 0.2 mg/ml 
NaH2PO4 · H2O 2.14 mg/ml 
PK-Buffer   
Tris 200 mM 
NaCl 1 M 
EDTA 40 mM 
T-Buffer   
Tris 10 mM 
TE-Buffer   
Tris 10 mM 
EDTA 1 mM 
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TAE-Buffer   
Tris 2 M 
EDTA 50 mM 
1.8.2 Media for in vitro production of embryos 
Stocks   
Pyruvate stock 2,2 mg/ml pyruvic acid in 0.9% NaCl 
solution 
Heparin stock 0.5 mg/ml heparin in Fert Talp stock 
Gentamycin stock 50 mg/ml gentamycin sulfate in 0.9% 
NaCl solution 
L-gluthamine stock 200 mM in ddH2O 
FSH stock 5 Units/ml in 0.9% NaCl 
LH stock 2.5  Units/ml in 0.9% NaCl 
Maturation medium (Modified Parker's Medium, MPM) 
Solution 1:   
Calcium L-lactate hydrate in ddH2O 6 mg/ml 
Soultion 2:   
NaHCO3 3 mg/ml 
HEPES  1.4 mg/ml 
Pyruvat 0.25 mg/ml 
Gentamycin-Stock µl 1.1 mg/ml 
TCM 199 10x (Life Technologies) 100 µl/ml 
Maturation medium (MPM):   
Solution 1 + solution 2 1+10  
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Supplementation (10 ml): 
FSH stock 50 µl (=0.025 U/ml) 
LH stock 50  µl (=0.0125 U/ml) 
OCS 500 µl 
Medium for in vitro fertilization (Fert Talp) 
NaCl 6.66 mg/ml 
KCl 0.235 mg/ml 
NaHCO3 2.103 mg/ml 
NaH2PO4H2O 0.047 mg/ml 
Penicilline 0.065 mg/ml 
Phenol red 0.01 mg/ml 
Na lactate sirup (1.3 g/ml) 1.86 µl/ml 
MgCl2H2O 0.1 mg/ml 
CaCl2H2O 0.397 mg/ml 
Supplementation (10 ml):   
Bovine serum albumin 60 mg 
Pyruvate stock 100 µl 
Heparin stock 300 µl 
Medium for sperm capacitation (Sperm Talp) 
NaCl 5.8 mg/ml 
NaHCO3 2.09 mg/ml 
NaH2PO2H2O 0.04  mg/ml 
HEPES 2.38 mg/ml 
MgCl2H2O 0.31  mg/ml 
CaCl2H2O 0.384  mg/ml 
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Phenol red 0.01  mg/ml 
Na lactate sirup (1.3 g/ml) 3.65 µl/ml 
Supplementation (10 ml):   
Bovine serum albumin 60 mg 
Pyruvate stock 500 µl 
Medium for in vitro culture (synthetic oviduct fluid, SOF) 
NaCl 62.92 mg/ml 
KCl 0.53 mg/ml 
KH2PO4 0.162 mg/ml 
CaCl2H2O 0.248 mg/ml 
MgCl2H2O 0.096 mg/ml 
NaHCO3 2.106 mg/ml 
Phenol red 0.0014  mg/ml 
Pyruvate 0.363  mg/ml 
L-gluthamine stock 5 µl/ml 
Na lactate sirup (1.3 g/ml) 0.47  µl/ml 
Supplementation (10 ml):   
BME Amino acid solution 400 µl 
MEM Amino acid solution 100 µl 
OCS 500 µl 
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1.8.3 Media for embryo manipulation and fixation 
HEPES-buffered Tyrode's medium with 0.1% PVA (TL-HEPES-PVA) 
NaCl 6.65 mg/ml 
KCl 0.24 mg/ml 
NaHCO3 0.17 mg/ml 
NaH2PO4 0.04 mg/ml 
Sodium lactate 1.12 mg/ml 
CaCl2 0.22 mg/ml 
MgCl2 0.05 mg/ml 
HEPES 2.38 mg/ml 
Phenol red 0.01 mg/ml 
Glucose 0.9 mg/ml 
Sorbitol 8 mg/ml 
Stroptomycin sulfate 0.05 mg/ml 
Penicillin-G 0.065 mg/ml 
Protease in PBS   
Protease P5147 5 mg/ml 
PVA 1 mg/ml 
Albertini-solution for fixation of embryos   
Pipes (0.5 M) 200 µl 
MgCl2 (50 mM) 100 µl 
EGTA (50 mM) 50 µl 
Deuteriumoxid 445 µl 
Paraformaldehyde (10%) 200 µl 
Triton X-100 5 µl 
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Aprotinin 1 µl 
Taxol (5 mM) 0.2 µl 
Total volume  1001.2 µl 
1.8.4 Media for cell culture 
Culture medium   
DMEM (1x) + GlutaMAX (GIBCO by life technologies) supplemented with  
Non-essential amino acids (100 ×) 1 % 
β-mercaptoethanol 0.1 mM 
Fetal calf serum (FCS) 10 - 15 % 
Stop medium   
DMEM (1x) + GlutaMAX (GIBCO by life technologies) supplemented with 
FCS 10 % 
Starvation medium   
DMEM (1x) + GlutaMAX (GIBCO by life technologies) supplemented with 
Non-essential amino acids (100 ×) 1 % 
FCS 0.5 % 
Cryo medium   
FCS + DMSO 9+1  
Tryspin/EDTA   
0.5% Trypsin + 0.04% EDTA in PBS w/o Mg
2+
, Ca
2+
 
 
  
  
III. Materials and Methods 29 
2. Methods 
2.1 In vitro production of bovine embryos 
All embryos were produced in vitro according to a standard procedure including in 
vitro maturation (IVM) and in vitro fertilization (IVF) (HIENDLEDER et al., 2004). 
Ovaries were collected in PBS pre-warmed to 36° C at the local abattoir. Follicles 
with a diameter of 2-8 mm were aspirated with a vacuum pump set to 80-100 mmHg 
and after washing three times, obtained cumulus–oocyte complexes (COCs) were 
matured for 23 h in groups of 40 in 10 µl maturation medium per COC. Frozen-
thawed sperm of a bull with proven fertility was thawed for 10 sec in a 38° C warm 
water bath and prepared by the swim-up method. Four 10 ml tubes were filled with 
each 1 ml Sperm Talp medium and 50 µl of sperm were layered underneath. Tubes 
were incubated at 39° C and after 1 h, the upper layer of the tubes was collected and 
centrifuged at 500 rcf. The supernatant was removed and concentration was 
determined using a Neubauer improved counting chamber. Matured COCs were 
transferred to Fert Talp medium and co-incubated with 1x10
6 
sperm/ml. For IVM 
and IVF, COCs were incubated at 39° C in a maximum humidified atmosphere of 
5% CO2 in air. After 20 h of co-incubation, presumptive zygotes were vortexed for 3 
min to remove remaining cumulus cells and washed three times. Zygotes with no 
remaining cumulus cells were cultured in groups of 40 in 400 µl of synthetic 
oviductal fluid (SOF) under 400 µl mineral oil at 39° C in a maximum humidified 
atmosphere of 5% CO2, 5% O2, and 90% N2. 
2.2 Embryo manipulation 
All embryo manipulations were performed on a heated microscope plate set to 36° C. 
Where not indicated differently, embryos were transferred to drops of TL-HEPES-
PVA for handling outside the incubator (KUROME et al., 2015). 
2.3 Zona pellucida removal 
On Day 4, 5 or 7 of embryonic development, the ZP was removed by treatment with 
5 mg/ml of protease for 1 minute. Enzyme reaction was stopped by washing embryos 
in TL-HEPES-PVA supplemented with 10% fetal calf serum. Dissolved ZP was 
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completely removed by gentle pipetting with a finely drawn glass pipet with sharp 
ends and an inner diameter of 80 µm. 
2.4 Morula disaggregation 
To disaggregate morulae after ZP removal, they were incubated for 20 min in drops 
of PBS w/o Mg
2+
, Ca
2+ 
supplemented with 0.1% PVA under oil on a heated 
microscope stage set to 36° C. Through pipetting with a blunt glass pipet with an 
inner diameter of 80 µm, blastomeres were completely individualized. 
2.5 Chimera production 
Chimeras were produced from two ZP-free day 4 host embryos (~16 cells) that did 
not complete their first cleavage until 27 h after IVF and two blastomeres from a day 
5 eGFP transgenic embryo (donor), produced by using semen from an eGFP 
transgenic bull for IVF (REICHENBACH et al., 2010). Alternatively, chimeras were 
produced from two day 4 OCT4 knockout (KO) host embryos derived from 
WalterBF-Tg(PGK-EGFP)POU5F1
1AH1tm1 
fibroblasts and four blastomeres of a day 
4 wild-type in vitro produced embryo. The chimera production scheme is shown in 
Figure 4. 
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Figure 4: Chimera production scheme 
2.5.1 Sandwich technique 
In the sandwich technique, first a host embryo was transferred to a depression of a 
4x4 WoW culture dish (Primovision embryo culture dish) with 160 µl SOF covered 
by mineral oil. Subsequently, the donor blastomeres were added and topped by the 
second host embryo to ensure close contact of the chimera’s constituents and to 
position the donor blastomeres in between the hosts (BERG et al., 2011).  
2.5.2 Aggregation technique 
Host embryos were washed in SOF and transferred in pairs to drops of SOF 
supplemented with 150 µg/ml PHA and incubated for 20 min under embryo culture 
conditions. After incubation, pairs of blastomeres from the donor embryo were added 
to the drops and pushed in between the two host embryos with a closed and finely 
drawn pipet, so the blastomeres stuck firmly to the host embryos. Stable constructs 
were subsequently washed in SOF and transferred individually into the depressions 
of a WoW culture dish. The aggregation technique is shown in Figure 5. 
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Figure 5: Aggregation of two day 4 host embryos and two day 5 donor blastomeres using 
PHA. A: two host embryos stuck together after incubation in SOF + PHA  for 20 min. B: two 
donor blastomeres added to the drop. C: after sticking the donor blastomeres together, they 
are positioned in between host embryos. D: donor blastomeres are pushed firmly against 
host embryos. Adapted from SIMMET et al. (2015a).  
2.6 Time lapse imaging 
To compare the development of chimeras produced by the different techniques, 
WoW culture dishes were placed into the Primo Vision embryo monitoring system 
(Vitrolife, Gothenburg, Sweden). Images were recorded every 5 min for 96 h. 
2.7 Cell culture procedures 
All solutions and media were prewarmed to 37° C before use, unless indicated 
otherwise. Cells were incubated at 38.5° C in a maximum humidified atmosphere 
with 5% CO2 in air and centrifuged at 500 rcf for 5 min. Previously isolated bovine 
fibroblast cells from an eGFP transgenic bull (WalterBF-Tg(PGK-EGFP)) were 
thawed at room temperature by adding Stop medium to the cryo vial. Cells were 
transferred to an adequate tube and centrifuged. The pellet was resuspended in 
culture medium and cells were seeded on plates appropriate to the amount of cells 
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(1.4 - 1.6 cells/cm
2
). To harvest the cells after attachment to the culture dish, cells 
were washed twice with PBS w/o Mg
2+
, Ca
2+
 and after adding trypsin/EDTA 
solution incubated for 3 min. Trypsin reaction was stopped with Stop medium and 
cells were centrifuged for further processing. To freeze cells, the pellet was 
resuspended with Cryo medium cooled to 4° C and transferred to a cryo vial, which 
was cooled slowly in a CoolCell device (BioCision) over night at -80° C before 
storage in liquid nitrogen (LN2).   
2.8 CRISPR/Cas9 mediated production of OCT4 knockout host 
embryos 
2.8.1 CRISPR/Cas9 design 
To knock out the OCT4 gene in bovine adult fibroblast cells, a CRISPR/Cas9 system 
was employed. A sgRNA was designed to bind at exon 2 of the OCT4 gene (Figure 
6) using chopchop software (MONTAGUE et al., 2014). The construct expressing 
the fusion of the sgRNA and tracrRNA, as well as a construct expressing Cas9 
according to MALI et al. (2013) was purchased from Life Technologies, Invitrogen.  
 
 
Figure 6: OCT4 gene, sgRNA and Cas9 cutting site 6 bp upstream from the protospacer 
adjacent motif (PAM, red letters). 
 
2.8.2 Transfection of adult fibroblasts 
Transfection of adult fibroblasts was performed with the Nucleofector
TM 
device and 
the Amaxa
TM 
Basic Nucleofector
TM 
Kit for primary fibroblasts including Basic 
Nucleofector
TM
 solution, cuvettes and Pasteur pipets. 1x10
6 
eGFP transgenic
 
cells 
from WalterBF-Tg(PGK-EGFP) were seeded on a 10 mm culture dish and cultured 
for 24 h to obtain mainly mitotic cells. Subsequently, 0.5x10
6 
cells were resuspended 
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with Basic Nucleofector
TM
 solution at room temperature and each 1 µg of CRISPR 
and Cas9 plasmid was added to the suspension, which was then transferred to the 
cuvette. Transfection was performed using the predefined program U12 from the 
Nucleofector
TM 
device and the suspension was added to culture medium, equilibrated 
in a well of a 6-well plate, using the Pasteur pipet included in the kit. 24 h after 
transfection, the culture medium was renewed.   
2.8.3 Selection of single cell clones 
To produce single cell clones, each 100 cells from the previous transfection were 
seeded on 10x 96-well half area plates and culture medium was exchanged every 
three days. Five days after seeding, plates were scanned daily for single cell clones 
using Cellavista (Synentec), a fully automated cell imaging device that photographs 
each well and stores the pictures so development and integrity of single cell clones is 
documented. At 80% confluence, single cell clones were harvested and split on two 
wells of 96-well plates. When full confluence was reached, cells of one well were 
cryopreserved as backup and cells from the second well were used for DNA isolation 
to screen for mutations.   
2.8.4 DNA isolation 
DNA isolation from fibroblast cells was achieved through precipitation of DNA in a 
solution with a high salt concentration. After centrifugation, the cell pellet was 
resuspended with 100 µl PK-buffer, 10 µl SDS (10%) and 4.4 µl DTT (1 M) and 
incubated for 1 h at 60° C. 2 µl proteinase K (20 mg/ml) were added and incubation 
was continued for another 1 h. After addition of 30 µl NaCl solution (4.5 M) and 
incubation on ice for 10 min, specimens were centrifuged at 16.000 rcf for 20 min 
and the supernatant was transferred to a fresh reaction tube. 110 µl isopropanol were 
added and tubes were shaked carefully but thoroughly and centrifuged at 16.000 rcf 
for 20 min. The supernatant was discarded and 500 µl ethanol (70%) were added to 
wash the pellet. After storage over night at 4° C, tubes were centrifuged again at 
16.000 rcf, 5 min, the ethanol was removed and the pellet air dried for 6 min. The 
pellet was then dissolved in 35 µl T-buffer and incubated for 1 h at 60° C. After 
vortexing, DNA was ready for further processing.  
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2.8.5 Screening of single-cell clones 
To identify single-cell clones with mutations in the OCT4 gene after transfection 
with CRISPR/Cas9, a PCR product from the mutation site was analyzed with Sanger 
sequencing. The PCR components were mixed on ice to a final volume of 25 µl in 
0.2 ml reaction tubes. Previously isolated genomic DNA from single cell clones 
served as template and water was used as a non-template control. Details for master 
mix ingredients and PCR conditions are listed in Table 1 and Table 2. 
Table 1: PCR components 
Herculase II 5x reaction buffer 5.0 µl 
dNTPs 2.5 µl 
Forward Primer, 10 mM (OCT4 2f) 0.4 µl 
Reverse primer, 10 mM (OCT4 2r) 0.4 µl 
Herculase II Fusion DNA Polymerase 0.2 µl 
Water 15.5 µl 
Template 1.0 µl 
 
Table 2: OCT4 PCR cycler protocol 
Denaturation 4 min 95° C  
Denaturation 20 sec 95° C  
Annealing 20 sec 56° C x 35 
Elongation 40 sec 72° C  
Final elongation 10 min 72° C  
Termination 15 min 4° C  
For purification, PCR products were precipitated by adding 2.5 µl NaAc (3.5 M) and 
60 µl ethanol (100%) and storage at -80° C for 30 min. After centrifugation for 30 
min at 4° C and 16000 rcf, the pellet was washed in 100 µl ethanol (70%) and 
dissolved in 20 µl T-buffer. To verify presence and size of the PCR products, 2.5 µl 
bromophenolblue were added to 10 µl of precipitated PCR product and inserted to 
individual gel slots of a 1% agarose gel with 0.5 µg/ml ethidium bromide in a 
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chamber filled with TAE buffer. For determination of the fragment size, 6 µl of Gene 
Ruler
TM
 1 kb was added to an additional gel slot and an electrical field of 130 V was 
applied to start electrophoresis and after approximately 30 min, bands were 
visualized under UV-light. Positive PCR products were then used for the Sanger 
sequencing reaction, whose components and conditions are listed in Table 3 and 
Table 4.   
Table 3: Sequencing reaction components 
5x sequencing buffer 4 µl 
BigDye 1 µl 
Primer, 10 mM (OCT4 2f) 1 µl 
Water 2 µl 
Template 2 µl 
 
Table 4: Sequencing reaction cycler protocol 
Denaturation 1 min 95° C  
Denaturation 5 sec 95° C  
Annealing 10 sec 52° C x 40 
Elongation 4 min 60° C  
Termination 15 min 4° C  
To purify the products from the sequencing reaction, precipitation was essentially 
performed as described above. 2.5 µl EDTA (125 mM) and 30 µl ethanol (100%) 
were added and tubes were incubated on ice for 15 min. After centrifugation and 
washing with ethanol (70%), samples were dissolved in water and transferred to a 
96-well sequencing plate. Analysis of the samples was carried out by the Genome 
Analysis Center at the Helmholtz Zentrum Munich. Sequences were analyzed with 
FinchTV Version 1.3.1 and the BioEdit Sequence Alignment Editor (HALL, 1999).  
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2.9 Somatic cell nuclear transfer 
Somatic cell nuclear transfer experiments were conducted by PD Valeri 
Zakhartchenko as described in HIENDLEDER et al. (2004). Briefly, COCs were 
retrieved and matured as described in III.2.1. After 18-20 h of maturation, oocytes 
were denuded, treated with 5 µg/ml cytochalasin B and enucleated. Trypsinized 
somatic donor cells, cultured in starvation medium for 24 h, were placed into the 
perivitelline space and fused to the enucleated oocyte by applying a double electric 
pulse of 2.1 kV/cm for 10 µsec. 2 h after fusion, fused complexes were activated in 
ethanol (7%), followed by a 5 h culture in 10 µg/ml cycloheximide and 5 µg/ml 
cytochalasin B. After activation, cloned embryos were cultured as described in 
III.2.1.  
2.10 Control embryos 
To analyze the influence of ZP removal, PHA and overall handling on embryo 
development, day 5 embryos were exposed to SOF supplemented with 150 µg/ml 
PHA for 20 min in individual drops after removing the ZP, washed in SOF and 
transferred to a WoW culture dish. While removing the ZP of embryos for PHA 
exposure, a subset of embryos was kept outside the incubator in TL-HEPES-PVA as 
handling control for further culture in a WoW culture dish. To verify complete OCT4 
KO and to describe the OCT4 KO phenotype, embryos derived from WalterBF-
Tg(PGK-EGFP) fibroblasts served as controls in all experiments. Additionally, 
embryos reconstructed from the single cell clone ETF1mut
2F11tm1
 were produced to 
assess a possible effect of the off-target mutation in the ETF1 gene (see IV.2.2).  
2.11 Albertini fixation of embryos 
For imaging, embryos were fixed in a microtubule stabilization buffer containing 2% 
paraformaldehyde (MESSINGER & ALBERTINI, 1991; LEIDENFROST et al., 
2011). Fixation solution was prepared fresh and equlilibrated at 37° C every time. 
Embryos were washed in PBS supplemented with 0.1% PVA (PBS/PVA) and then 
transferred to the fixation solution and incubated at 37° C for 20 min. Fixed embryos 
were subsequently washed three times in PBS/PVA and stored in said  
medium at 4° C.  
  
III. Materials and Methods 38 
2.12 Imaging procedures 
2.12.1 Imaging of chimeric embryos 
After culture for 96 h, all chimeras were retrieved from the WoW culture dish and 
individual depressions within the WoW were checked for not-integrated aggregation 
partners. Only complete chimeras were considered blastocysts and evaluated for 
integration of eGFP positive donor blastomeres using an inverted epifluorescence 
microscope (Axiovert 200 M; Zeiss, Oberkochen, Germany) with the adequate filter 
set (excitation: 470/40, emission: 525/50). A subset of chimeras was stained for the 
TE-specific transcription factor CDX2 to differentially stain TE and ICM (MADEJA 
et al., 2013). Fixed blastocysts were incubated in a 1:200 dilution of rabbit anti-
CDX2 polyclonal antibodies for 30 min at 37° C, washed three times in PBS/PVA 
and incubated in a 1:800 dilution of donkey anti-rabbit immunoglobulin G labeled 
with Alexa Fluor 555 for 30 min at 37° C. After washing again three times in 
PBS/PVA, blastocysts were placed on microscope slides in an antifade mounting 
medium with 40,6-diamidino-2-phenylindole (DAPI; VECTASHIELD) in a manner 
that conserves the three dimensional structure of the specimen (WUENSCH et al., 
2007).  
2.12.2 Immunofluorescent expression analysis  
Before fixation of day 5 morulae and day 7-9 blastocysts, the ZP of non-hatched 
embryos was removed. Prior to staining, embryos were incubated for 1 h at room 
temperature in a blocking solution containing 0.5% Triton X-100 and 5% donkey 
serum. Simultaneous staining for either OCT4 and CDX2 or NANOG and GATA6 
was achieved by incubation over night at 4° C in primary antibody solution and 
transfer to secondary antibody solution at 37° C for 1h after washing three times. For 
OCT4/CDX2 staining, dilution of goat anti-human OCT4 polyclonal antibodies and 
rabbit anti-human CDX2 polyclonal antibodies was 1:500 and 1:250, respectively. 
Secondary antibodies (donkey anti-rabbit Alexa Fluor 555 and donkey anti-goat 
Alexa Fluor 633) were both diluted 1:800. Staining of NANOG/GATA6 was 
performed with rabbit anti-human NANOG at 1:500 and goat anti-human GATA6 at 
1:250 with secondary antibodies at 1:500 (donkey anti-rabbit Alexa Fluor 555) and 
1:400 (donkey anti-goat Alexa Fluor 633). After washing, embryos were embedded 
  
III. Materials and Methods 39 
as described above. Specific binding of secondary antibodies was ensured by 
omitting the first antibody and possible cross-reactivity between primary and 
secondary antibodies was excluded by labeling one primary antibody with the 
secondary antibody specific to the other primary antibody in a simultaneous staining 
and vice versa. To control if secondary antibodies are binding incorrectly to each 
other, samples were incubated without the primary antibodies.    
2.12.3 Confocal microscopy 
Stacks of optical sections were recorded using an LSM710 Axio Observer confocal 
laser scanning microscope (CLSM; Zeiss) with an interval of 2.5 µm using a x25 
water immersion objective (LD LCI Plan-Apochromat 25x/0.8 Imm Korr DIC M27) 
and a pinhole of 32 µm. The settings for imaging of chimeras and expression 
analysis are presented in Table 5. 
Table 5: Settings for confocal laser scanning microscopy of embryos and chimeras. 
Wavelength of excitation/emission, laser line and filter in nm. 
 
Target 
Dye/ 
fluorophore 
Excitation/ 
Emission  
Track Laser line  Filter 
 DNA DAPI 358/461  Track 1 405  410 - 562  
 
      
E
x
p
re
ss
io
n
 a
n
al
y
si
s OCT4 Alexa 633 632/648  Track 1 633  638 - 747 
CDX2 Alexa 555 553/568  Track 2 561  582 - 631 
      NANOG Alexa 555 632/648  Track 2 561  562 - 611 
GATA6 Alexa 633 553/568  Track 1 633  638 - 747 
       
C
h
im
er
as
 
CDX2 Alexa 555 553/568  Track 1 561  566 - 697 
eGFP cells eGFP 488/509  Track 2 488  494 - 552 
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2.12.4 Image analysis 
Images were analyzed with icy bioimage analysis software (DE CHAUMONT et al., 
2012) using the manual counting plug-in, in which every slide of an image stack was 
analyzed individually to avoid double cell counts. The number of total cells was 
assessed by counting all the nuclei stained with DAPI, the number of TE, HB and 
EPI cells was determined by counting all the nuclei co-stained with DAPI and 
CDX2, GATA6 and NANOG, respectively. The number of cells in the ICM was 
calculated by subtracting the number of TE cells from the total cell number. Figures 
were produced with Fiji software (SCHINDELIN et al., 2012).  
2.13 Statistical analysis 
All data were analyzed with GraphPad Prism 5.02 using the two-tailed unpaired t test 
or the 1way ANOVA with Tukey‘s multiple comparison test for comparison of cell 
numbers and blastocyst rates. Fisher’s exact test was used for the development of 
wild-type chimeras and control embryos. Level of significance was set to P<0.05 and 
data are presented as mean ± standard deviation (SD).  
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IV. Results 
1. Chimeras with wild-type host embryos  
Results in this section have been published in SIMMET et al. (2015a), including 
Figures 7-9 and Tables 6-8.   
1.1 Host and donor embryo development 
1621 presumptive zygotes were produced for host embryos. 1370 (84.5%) did not 
complete their first cleavage until 27 h after IVF. Of these zygotes, 928 (52.7%) 
cleaved and 489 (35.7%) developed to day 4 morulae. A subset of host embryos 
(n=601) was cultured until day 7, of which 155 (25.8%) developed to blastocysts 
while in control embryos (n=506), that were not sorted according to timing of first 
cleavage, 210 (37.8%) developed to blastocysts (unpaired two-tailed t-test, P<0.05). 
For donor embryo production, 1744 presumptive zygotes were produced and 360 
(20.7%) developed to day 5 morulae. 169 morulae were analyzed for eGFP 
expression using fluorescent microscopy, of which 76 (45%) were eGFP positive. A 
subset of 150 zygotes was cultured until day 7, of which 23 (15.3%) developed to 
blastocysts with 17 (73.9%) showing eGFP fluorescence. 
1.2 Chimera development and donor blastomere integration 
Development of chimeras aggregated with PHA or by the sandwich technique and 
the respective integration of eGFP positive donor blastomeres to ICM, TE or both 
lineages is shown in Table 6 and Figure 7. Developmental kinetics of chimeras, as 
recorded with the embryo monitoring system, are shown in Figure 8.  
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Table 6: Development of chimeras and donor blastomere integration using the different 
aggregation techniques. Different superscripts within a row indicate significant differences 
(Fisher’s exact test, P<0.05). Adapted from SIMMET et al. (2015a). 
 PHA Sandwich 
N° chimera 99 46 
Blastocysts 85 (85.9%
a
) 25 (54.3%
b
) 
GFP ICM 34 (40%
a
) 4 (16%
b
) 
GFP ICM + TE 17 (20%
a
) 11 (44%
b
) 
No GFP 33 (38.8%
a
) 10 (40%
a
) 
GFP TE 1 (1.2%) 0 
 
 
Figure 7: Chimera produced with PHA and donor embryo integration to the ICM.  A: bright 
field with extended focus. B: eGFP positive donor cells in the ICM. Adapted from SIMMET 
et al. (2015a). 
 
A B 
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Figure 8: Development of chimeras aggregated with PHA (A) and by the sandwich technique 
(B) at 0 h, 16 h and 38 h after aggregation. Adapted from SIMMET et al. (2015a). 
1.3 Cell numbers 
Cell numbers of chimeras produced with PHA, embryos exposed to PHA and 
handling control embryos are shown in Table 7. Development from day 5 morula to 
day 9 blastocyst was 43/54 (79.6%) for embryos exposed to PHA and 23/32 (71.9%) 
for handling control embryos (P>0.05). 
Table 7:Mean ± SD of number of total cells, number of ICM cells, number of TE cells and 
ratio of ICM/total cells of chimeras (n=17), embryos exposed to PHA (n=30) and handling 
control embryos (n=19). Different superscripts within a row indicate significant differences 
(unpaired two-tailed t-test, P<0.05). Adapted from SIMMET et al. (2015a). 
 
Chimera PHA Handling Control 
Total cell number 207.8 ± 68.3
a
 159.6 ± 42.2
b
 176.9 ± 53.3
b
 
ICM 56.5 ± 22
a
 37.7 ± 14.2
b
 38.7 ± 12.4
b
 
TE  151.2 ± 58
a
 121.9 ± 37.4
b
 138.3 ± 53
a, b
 
ICM/Total 27.9% ± 8.8 23.1% ± 7.9 24% ± 8 
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1.4 CLSM analysis of chimeras with wild-type hosts 
Of 17 analyzed chimeras by CLSM, 8 showed no eGFP expression and 9 chimeras 
showed donor blastomere integration to the ICM, the TE or both lineages. Three 
blastocysts showed integration of eGFP positive blastomeres to the ICM with 16, 14 
and 5 blastomeres, respectively. Each 10, 4 and 2 eGFP blastomeres colonized the 
TE and integration to both cell lineages occurred in three blastocysts with 8 and 1, 5 
and 1, and 2 and 2 blastomeres integrated to the ICM and TE, respectively. Further 
cell number data on chimeras are presented in Table 8 and representative images of a 
chimera are shown in Figure 9. 
Table 8: Cell counts of chimeric blastocysts including number of eGFP positive cells 
according to allocation of eGFP positive blastomeres (mean ± SD). Adapted from SIMMET 
et al. (2015a). 
 
 
Total cell 
number TE ICM eGFP ICM 
eGFP 
TE 
Chimeras with eGFP  
in ICM (n=3) 
251.3 ± 39.6 172.3 ± 39.3 79 ± 23.3 11.67 ± 5.9 - 
Chimeras with eGFP  
in ICM and TE (n=3) 
154.3 ± 53.7 103.3 ± 34.6 51 ± 32.1 5 ± 3 1.3 ± 0.6 
Chimeras with eGFP 
in TE (n=3) 
142.7 ± 45.4 111 ± 45.4 31.7 ± 9.1 - 5.3 ± 4.2 
Chimeras with  
no eGFP (n=8) 
235.9 ± 63.7 176.4 ± 61 59.5 ± 11.2 - - 
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Figure 9: Single slices and 3D projection of CLSM image of a chimera with eGFP donor 
blastomere integration to the ICM. A: all nuclei stained with DAPI. B: TE cells stained with 
anti-CDX2 antibody. C: eGFP positive blastomeres. D: merged image of A, B and C. E, F: 
two images from different angles (0° and 180°). Adapted from SIMMET et al. (2015a). 
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2. OCT4 knockout embryos 
2.1 CRISPR/Cas9 targeting efficiency 
After seeding the transfected cells on ten 96-well half area culture plates, 156 single 
cell clones were identified, propagated and screened for mutations, resulting in a 
total of 4 (2.6%) single cell clones with mutations. One single cell clone (WalterBF-
Tg(PGK-EGFP)POU5F1
1AH1tm1
), which was used for further experiments, carried a 
biallelic deletion of a single nucleotide that leads to a frameshift mutation (Figure 
10). The biallelic mutation was confirmed with the continuous chromatogram from 
Sanger sequencing downstream of the deletion (Figure 10) and with a conserved 
SNP 200 bp downstream from the PAM (Figure 11), sequenced with the OCT4 11f 
primer.  
 
Figure 10: Chromatogram and mutation of WalterBF-Tg(PGK-EGFP)POU5F1
1AH1tm1
 on 
DNA, RNA and protein level; “wt” represents the reference genome (NCBI gene ID: 
282316) with sgRNA in italics and the PAM underlined. 
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Figure 11: Chromatogram of conserved SNP 200 bp downstream from mutation site in non-
transfected cells (WalterBF-Tg(PKG-EGFP)) and mutated single cell clone (WalterBF-
Tg(PKG-EGFP)POU5F1
1AH1tm1
). 
2.2 CRISPR/Cas9 off target effects 
Because OCT4 is silenced in somatic cells, a low targeting efficiency due to a low 
accessibility of the gene was assumed when designing the sgRNA. Therefore, from 
the sgRNAs generated by chopchop software, the most promising sgRNA regarding 
specificity and efficiency scores was used (boOCT4 sgRNA, see III.1.5). Also, to 
cover all OCT4 isoforms, exon 2 was selected as sgRNA binding site, as this exon is 
included to all known splicing variants of the human OCT4 protein (WANG & DAI, 
2010). A pitfall in designing the sgRNA for the bovine OCT4 locus, is the presence 
of an OCT4 pseudogene, where the OCT4 transcript, including exon 1-4 and the first 
27 bp of exon 5, is integrated to the first intron of the eukaryotic translation 
termination factor 1 gene (ETF1) on chromosome 7 (SCHIFFMACHER & KEEFER, 
2013). The boOCT4 sgRNA was analyzed for off-target effects with the web 
application e-crisp (HEIGWER et al., 2014), which also offers the bovine reference 
genome. The same specificity and efficiency scores as for the OCT4 target were 
found within the ETF1 gene, but it was not possible to design a different sgRNA that 
meets the above mentioned requirements (high efficiency and coverage of all 
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splicing variants) without targeting the OCT4 pseudogene. Therefore, the off target 
site of 22 single cell clones was analyzed for mutations to examine the degree of the 
off target effects. The locus was amplified with primers ETF1 2f and ETF1 2r and 
then sequenced with the primers ETF1 3f and ETF1 2r; 8 (36%) clones carried a 
mutation, including WalterBF-Tg(PKG-EGFP)POU5F1
1AH1tm1
. Its monoallelic 
mutation of a single nucleotide is shown in Figure 12, where the chromatograms of 
the forward and reverse sequences both break up at the same position, due to a 
deleted nucleotide on one allele.   
 
Figure 12: Monoallelic deletion of a single nucleotide (in brackets) on off target site in 
single cell clone WalterBF-Tg(PKG-EGFP)POU5F1
1AH1tm1
. 
We identified one single cell clone (ETF1mut
2F11tm1
) that carries the exact same 
mutation as WalterBF-Tg(PKG-EGFP)POU5F1
1AH1tm1
 in the ETF1 off target gene 
but no mutation in the OCT4 gene. Embryos reconstructed from these cells served as 
additional controls to identify possible effects of the mutation in ETF1 on 
developmental rates. 
2.3 Somatic cell nuclear transfer 
To analyze the phenotype of embryos derived from the single cell clone WalterBF-
Tg(PGK-EGFP)POU5F1
1AH1tm1 
(OCT4 KO), and thereby the effect of an OCT4 KO 
in bovine preimplantation embryos, embryos were reconstructed with SCNT. 
Embryos derived from the non-transfected cell line WalterBF-Tg(PGK-EGFP) 
served as controls (NT CTRL). Morphology of the embryos at day 7 and day 9, 
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including eGFP expression (recorded as described in III.2.12.1), is shown in  
Figure 13. By day 7, OCT4 KO and NT CTRL embryos showed normal blastocyst 
morphology with a discernable ICM and TE, also blastocysts began to expand by day 
7 as evidenced by a thinner ZP. At day 9, blastocysts of both groups were able to 
hatch from the previously opened ZP (assisted hatching) and NT CTRL blastocysts 
evidently exceeded OCT4 KO blastocysts in size. Both groups expressed eGFP until 
day 9. 
 
Figure 13: Brightfield images with extended focus, eGFP expression and the merge of OCT4 
KO (A) and NT CTRL (B) day 7 blastocysts and OCT4 KO (C) and NT CTRL (D) day 9 
hatched blastocysts. Scale bars represent 100 µm. 
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Developmental rates of OCT4 KO and NT CTRL embryos are presented in Table 9. 
There was no significant difference in cleavage rate or development to morula stage 
between OCT4 KO and NT CTRL; blastocyst rate by day 7 was strongly decreased 
in OCT4 KO embryos because of a lower morula to blastocyst transition rate. 
Table 9: Development of cloned embryos to day 7 blastocysts. Rates are calculated based on 
the number of successful fusions and presented as mean [%] ± SD; [n] represents the 
number of experiments. Different superscripts within a row indicate significant differences 
(P<0.05, unpaired, two-tailed t-test). 
 WalterBF-Tg(PGK-
EGFP)OCT4ko
1AH1tm1
 
n=21 
WalterBF-Tg(PGK-EGFP) 
n=18 
N° constructs 765 474 
Fused (fusion rate) 741 (96.3 ± 4
a
) 439 (91.8 ± 5.7
b
) 
Cleaved (cleavage rate) 516 (69.5 ± 13.1
a
) 266 (64.4 ± 13.1
a
) 
Day 5 morula (morula rate)  252 (34.7 ± 18.7
a
) 153 (36.1 ± 11.6
a
) 
Day 7 blastocyst (blastocyst rate) 125 (16.78 ± 10.21
a
) 135 (32.07 ± 10.84
b
) 
Blastocysts/morula  45.78 ± 24.54
a
 89.27 ± 11.39
b
 
213 fused constructs were produced with the single cell clone ETF1mut2F11tm1 
(see IV.2.2) in three experiments. There was no significant difference (P>0.05, 1-
way ANOVA with Tukey's Multiple Comparison Test) to the development of NT 
CTRL or OCT4 KO embryos with a blastocyst rate of 22.6 ± 8.8% (mean ± SD).  
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2.4  Immunofluorescence analysis  
2.4.1 OCT4 and CDX2 
To confirm the absence of OCT4 protein in OCT4 KO embryos and to differentially 
stain ICM and TE in blastocysts, day 5 morulae and day 7 blastocysts from OCT4 
KO, NT CTRL and from in vitro produced embryos (IVP CTRL) were stained 
against OCT4 and CDX2 simultaneously. Only day 5 morulae that exceeded a total 
cell count of ≥ 32 cells were included to the analysis. While NT CTRL and IVP 
CTRL morulae expressed OCT4 in all cells, OCT4 KO morulae showed expression 
in only 67.8% ± 11.1 (mean ± SD, n=6) of cells and overall intensity was decreased. 
In none of the embryos, CDX2 was expressed in the nuclei but detected in the 
cytoplasm (Figure 14).  
 
Figure 14: Single slices of confocal images of day 5 morulae stained against OCT4 and 
CDX2. 
In day 7 blastocysts, OCT4 was no longer detectable in OCT4 KO embryos, while 
control embryos ubiquitously expressed OCT4. In all embryos, CDX2 was expressed 
in the nuclei and restricted to TE cells (Figure 15).  
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Figure 15: Single slices of confocal images of day 7 blastocysts stained against OCT4 and 
CDX2.   
The number of total cells and the percentage of OCT4 and CDX2 positive cells for 
day 7 blastocysts from SCNT (OCT4 KO and NT CTRL) and from embryos derived 
from in vitro fertilization (IVP CTRL) are shown in Table 10. 
Table 10: Total cell number and percentage of OCT4 and CDX2 positive cells for OCT4 KO, 
NT CTRL and IVP CTRL day 7 blastocysts. [n] represents number of analyzed blastocysts 
per group. Different superscripts within a row indicate significant differences (P<0.05, 1way 
ANOVA with Tukey‘s multiple comparison test). 
 OCT4 KO 
n=24 
NT CTRL 
n=20 
IVP CTRL 
n=40 
Total cell number 89.6 ± 27.5
a 
96.3 ± 38
a 
125.8 ± 36.5
b 
[%] OCT4 positive cells 0
a 
78.8 ± 10.5
b 
77.2 ± 16.4
b 
[%] CDX2 positive cells 56.8 ± 11.5 62.5 ± 9.6 59.3 ± 9.2 
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2.4.2 NANOG and GATA6 
To investigate the role of OCT4 during the second lineage differentiation, day 5 
morulae, day 7 blastocysts and day 9 hatched blastocysts were analyzed for 
expression of the HB and EPI specific markers GATA6 and NANOG, respectively. 
At day 5, all embryos co-expressed both markers and OCT4 KO embryos showed the 
same expression pattern as NT CTRL and IVP CTRL embryos (Figure 16), although 
the percentage of GATA6 positive cells was significantly decreased. Detailed data 
for total cell numbers and percentage of GATA6 and NANOG positive cells in day 5 
morulae is provided in Table 11.   
 
Figure 16: Single slices of confocal images of day 5 morulae stained against GATA6 and 
NANOG. 
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Table 11: Total cell number and percentage of GATA6 and NANOG positive cells for OCT4 
KO, NT CTRL and IVP CTRL day 5 morulae. [n] represents number of analyzed morulae 
per group. Different superscripts within a row indicate significant differences (P<0.05, 1way 
ANOVA with Tukey‘s multiple comparison test). 
  OCT4 KO NT CTRL IVP CTRL 
n=9 n=14 n=7 
Total cell number 55 ± 13.3 65.9 ± 15.7 56.1 ± 12 
[%] GATA6 positive cells 60.4 ± 13.9
a
 92.7 ± 7.7
b
 89.5 ± 5.5
b
 
[%] NANOG positive cells 80.5 ± 9.2
a
 92.9 ± 7
b
 84.7 ± 10.3
a,b
 
In day 7 blastocysts, NT CTRL (n=13) and IVP CTRL (n=6) embryos already 
showed the typical salt and pepper distribution of NANOG and GATA6 positive 
cells, but expression was not mutually exclusive in all cells. When the factors were 
co-expressed, fluorescent intensity of both was decreased, compared to their 
exclusive expression. Also expression was not restricted to the ICM, as cells from the 
TE also still stained positive for both markers (Figure 17). In SCNT CTRL day 7 
blastocysts, 7.1 ± 2.9%  and 9.8 ± 4% of cells stained exclusively positive for 
NANOG and GATA6, respectively (n=13, mean ± SD, unpaired two-tailed t-test, 
P>0.05). OCT4 KO embryos (n=8) lost all NANOG expression at day 7 blastocyst 
stage and only stained positive for GATA6 in a similar pattern as NT CTRL 
blastocysts with a few cells of higher intensity (Figure 17). 
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Figure 17: Single slices of confocal images of day 7 blastocysts stained against GATA6 and 
NANOG. 
Expression of NANOG and GATA6 was mostly limited to cells of the ICM and 
mutually exclusive in NT CTRL (n=7) and IVP CTRL (n=3) day 9 hatched 
blastocysts (Figure 18). OCT4 KO blastocysts (n=6) showed no expression of 
NANOG or GATA6, also there were no packed cells as indicative for an ICM. The 
total cell number of OCT4 KO embryos (n=6) was strongly decreased when 
compared to NT CTRL (n=7) by day 9 (139.2 ± 33.5 vs. 319.7 ± 70.51, mean ± SD, 
unpaired two-tailed t-test, P<0.05) 
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Figure 18: Single slices of confocal images of day 9 hatched blastocysts stained against 
GATA6 and NANOG. 
After in vitro culture for 9 days, cells from the ICM predominantly contained 
degenerated cell nuclei in all embryos, so the majority of cells in the ICM could not 
be examined for expression of EPI or HB specific markers (Figure 19). This made 
further analysis of events during the second lineage differentiation in in vitro 
cultured day 9 blastocysts futile. 
 
Figure 19: Day 9 hatched NT CTRL blastocyst cultured in vitro. A: single slice of a confocal 
image with NANOG (green), GATA6 (red) and nuclei counterstained with DAPI (grey). 
Rectangle in A marks enlarged ICM, shown in B (DAPI), C (NANOG), D (GATA6) and E 
(merge of B,C and D). 
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3. Chimeras with OCT4 KO host embryos 
Chimeras with OCT4 KO host embryos from SCNT and wild-type donor cells from 
IVP embryos were produced like chimeras with wild-type hosts, except asynchronic 
aggregation, which was omitted to solely study the effect of OCT4 KO in hosts on 
donor blastomere integration in the chimera (see III.2.5). In four experiments using 
day 4 morulae as hosts and donors, 32 aggregates were cultured of which 24  
(74 ± 28.1%, mean ± SD) developed to blastocysts. Developmental kinetics of 
chimeras with OCT4 KO hosts did not differ from development of wild-type 
embryos aggregated with PHA, showing the same tight compaction of the 
aggregation partners to one morula before developing the blastocyst cavity (Figure 
20).  
 
Figure 20: Development of chimera with OCT4 KO embryos as hosts at 0 h, 16 h and 38 h 
after aggregation. 
At 96 h after aggregation, expansion of the blastocyst was not as marked as in  
wild-type chimeras and when washing the developed blastocysts before fixation, they 
lost a substantial amount of loosely attached cells, which was not observed with 
chimeras from wild-type donor hosts. Brightfield and eGFP fluorescence images 
from a developed chimeric blastocyst are shown in Figure 21.  
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Figure 21: Chimera produced with two OCT4 KO host embryos and four wild-type 
blastomeres at day 4. A: bright field with extended focus. B: eGFP expression with extended 
focus. 
13 chimeric blastocysts stained against CDX2 and OCT4 were analyzed with CLSM 
and 7 showed integration of donor blastomeres, as evidenced by the presence of 
OCT4 and the absence of eGFP in cells derived from the donor embryo. Co-staining 
with CDX2 allowed determination of lineage allocation of the aggregation partners 
(Figure 22). Donor cells colonized the ICM in 2 chimeric blastocysts with 8 and 15 
cells, making up 27.6% and 38.5% of the ICM, respectively. 2 chimeras with OCT4 
positive cells in the TE had a total cell number underneath the average of OCT4 KO 
day 7 blastocysts (see Table 10) with 69 and 67 cells, respectively. Further data on 
total cell number and percentage of OCT4 and CDX2 positive cells is presented in 
Table 12. 
Table 12: Total cell number and percentage of OCT4 and CDX2 positive cells for chimeras 
with OCT4 KO host embryos. [n] represents number of analyzed blastocysts per group.  
 Chimeras 
without OCT4  
(n=6) 
Chimeras with 
OCT4 in TE     
(n=5) 
Chimeras with 
OCT4 in ICM and 
TE (n=2) 
Total cell number 155.8 ± 37.1 123.3 ± 54.9 158 ± 22.6 
[%] OCT4 positive cells - 36.1 ± 19.6 21.9 ± 5.8 
[%] CDX2 positive cells 68.9 ± 12.3 72.2 ± 10.9 78.6 ± 1.4 
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Figure 22: Single slices of confocal images of chimera produced with two OCT4 KO host 
embryos and four wild-type blastomeres stained against OCT4 and CDX2. A: all nuclei 
stained with DAPI. B: TE cells stained with anti-CDX2 antibody. C: eGFP positive 
blastomeres from OCT4 KO hosts. D: OCT4 positive cells from donor. E: merge of B and C. 
F: merge of C and D. G: merge of A, B, C and D. Arrowheads and asterisks in F and G 
exemplarily show donor cells in the ICM and TE, respectively.   
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V. Discussion 
With the upcoming of genomic estimated breeding values (GEBV), the commercial 
value for positively selected embryos has increased dramatically. Therefore, a 
reliable embryo multiplication technique that is technically undemanding and highly 
efficient is sought. Multiplication of genotypes using chimeric complementation is a 
promising approach, because the techniques involved are relatively simple and 
resulting offspring does not suffer from artefacts associated to the method. Still, a 
major hurdle is to exclude host-embryo cells from the pluripotent lineage, so the 
fetus proper only develops from the desired genotype. Previous approaches using 
tetraploid complementation, as performed in the mouse, failed with bovine embryos, 
probably because electrofusion at the two-cell stage does not result in uniformly 
tetraploid embryos. In this thesis, new strategies for embryo multiplication via 
chimera complementation were examined, including the use of genetically modified 
host embryos that carry a KO of the pluripotency gene OCT4. In addition, this is to 
my knowledge the first report on the effects of an OCT4 KO in the bovine 
preimplantation embryo. 
Donor cells aggregated with wild-type host embryos fail to establish exclusively 
in the ICM of chimeras      
In chimeras aggregated from wild-type host embryos and transgenic donor 
blastomeres, eGFP expression enabled quantitative and spatial analysis of donor 
integration to the chimera, i.e. the number of donor-derived cells and their respective 
integration to ICM or TE. The eGFP transgenic donor embryos were produced by 
IVF using semen from an eGFP transgenic founder bull (“Jojo”), which was 
produced by lentiviral trangenesis and carries seven proviral integrants that segregate 
independently (HOFMANN et al., 2004; REICHENBACH et al., 2010). The rate of 
eGFP positive F1 embryos depends on the transmitted integrants and on possible 
epigenetic silencing of the reporter construct (HOFMANN et al., 2006), which in this 
study resulted in 45% and 73.9% eGFP positive day 5 morulae and day 7 blastocysts, 
respectively. Expression of eGFP additionally remains stable until day 15 in embryos 
and day 45 in fetuses (REICHENBACH et al., 2010), which would allow the use of 
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this system in experiments, where later developmental stages and allocation of the 
aggregation partners to different tissues or cell lineages, e.g. the primordial germ cell 
line, is of interest.  
To promote integration of the donor blastomeres to the ICM and to bias cells from 
the host embryos towards differentiation to extraembryonic tissues, host embryos 
that did not complete their first cleavage until 27 h after IVF were selected. These 
embryos contain more blastomeres with chromosomal aberrations (SUGIMURA et 
al., 2012), which are preferentially allocated in the TE. This is evidenced by a 
significantly higher proportion of polyploid cells in the TE as in the ICM (IWASAKI 
et al., 1992; VIUFF et al., 2002). The threshold of 27 h after IVF for completion of 
the first cleavage resulted in a significantly decreased blastocyst rate by day 7 when 
compared to non-sorted embryos. This indicates that embryos with an increased 
frequency of blastomeres with errors in the chromosomal setup were successfully 
selected applying above-mentioned parameter.  
When comparing the chimera aggregation techniques, a highly increased blastocyst 
rate when using PHA was recorded. The development of chimeras was observed 
using time lapse microscopy and chimeras aggregated with PHA tightly compacted 
to one single morula before developing the blastocoel cavity while compaction prior 
to blastocyst development was not visible that clearly in chimeras produced by the 
sandwich technique (see Figure 8). Additionally, integration of the donor 
blastomeres differed between aggregation techniques with PHA-chimeras showing a 
higher contribution of eGFP positive blastomeres to the ICM than sandwich-
chimeras (40% vs. 16%, p<0.05). Fixing the donor blastomeres in between the host 
embryos might direct them to the inside of the chimeric aggregate and favor ICM 
lineage commitment of the donor blastomeres. Because although the spatial context 
of a blastomere is not the only factor that defines its later commitment to a lineage, 
cells located on the inside of a morula are inclined to colonize the ICM (PFEFFER, 
2014).   
Using CLSM and immunofluorescent differential staining with a TE specific factor 
(CDX2), it was possible to accurately determine the total cell number and the 
number of TE-cells in aggregation chimeras with wild-type host embryos. 
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Unsurprisingly, the total cell number of chimeras exceeds the total cell number of 
control embryos. Nevertheless, considering the double cell number after aggregation, 
the difference is not marked. This brings up the question whether embryos have a 
certain mechanism to avoid excessive cell numbers before implantation to ensure 
normal development. The number of cells in the ICM of chimeras was increased 
when compared to control embryos; however, there were no significant differences 
between the groups in the ICM/total cell number ratio (see Table 7). Therefore, 
chimeras in this experiment had a normal ICM/TE ratio with functional cell lineages, 
shown by the positive, respectively negative staining of TE and ICM with the CDX2 
antibody. Interestingly, BANG et al. (2015) found contradicting results after 
aggregation of three day 3 transgenic morulae derived from SCNT. On day 8 of 
development, blastocysts derived by embryo aggregation had a threefold higher total 
cell number when compared to non-aggregated SCNT blastocysts. In addition, the 
increase was mainly due to a highly elevated number of TE cells resulting in a very 
low ICM/TE ratio of 1:4.8, whereas in this study, a slight increase in number of ICM 
cells was recorded. These data suggest that embryos from SCNT may react 
differently to aggregation then in vitro produced embryos. Evaluation of cell 
numbers in PHA treated and handling control embryos showed that ZP removal and 
PHA treatment had no significant effect.  
CLSM analysis of chimeras with wild-type host embryos confirmed that blastomeres 
from day 5 morulae are able to colonize the ICM when aggregated to day 4 host 
morulae. This enables the use of ex vivo derived embryos flushed from the uterus for 
multiplication via chimeric complementation, which bares many advantages. More 
cells are available, so more chimeras may be aggregated per donor embryo while 
enough cells are still available for simultaneous genotyping (PONSART et al., 2014). 
Also, in comparison to a study by HIRIART et al. (2013), who used day 3 donor and 
day 2 host embryos, blastocyst rates were highly increased with day 5 donor and day 
4 host embryos. Chimera production is probably improved, because at this 
developmental stage embryonic genome activation is already complete and embryos 
selected for aggregation do not suffer from developmental block (MEIRELLES et 
al., 2004; GRAF et al., 2014). CLSM also showed that none of the chimeras had 
exclusive ICM colonization by donor blastomeres and when integrated to the ICM, 
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they only represented a small portion of the pluripotent cell line (Table 8), indicating 
that only two donor blastomeres are too few to build a major part of the ICM. 
Additionally, CLSM revealed that chimera evaluation only by epifluorescence 
microscopy (Figure 7) is not reliable regarding the site and quality of donor 
blastomere integration. For example, the ICM of the chimera in Figure 9 would 
appear as fully colonized by eGFP positive blastomeres in epifluoresence 
microscopy. Nevertheless, a 3D projection of confocal sections of the chimera 
reveals that only few eGFP cells are found at the edge of the ICM and even seem to 
be developing into the hypoblast, which later forms the primitive yolk sac and does 
not contribute to the embryo proper (MADDOX-HYTTEL et al., 2003). Evaluation 
of such chimeras with epifluorescence microscopy would lead to false positive 
results regarding successful integration of donor blastomeres to the ICM and 
consequently the multiplication of a desired genotype, which in a species like cattle 
with long gestation periods and costly housing is not acceptable.  
OCT4 has no influence on the first lineage differentiation but KO embryos fail 
during the second lineage differentiation due to loss of NANOG 
To generate embryos with a KO of OCT4, somatic cells were transfected with 
CRISPR/Cas9. Cas9 is directed to the OCT4 locus by a specific sgRNA, where it 
induces a DSB. The error prone repair mechanism NHEJ then possibly leads to 
indels, which induce a shift in the reading frame of the gene and thus destroy its 
function. After screening 156 single cell clones, 4 (2.6%) showed mutation events of 
which only 1 clone carried a biallelic deletion that would induce a KO. Reported 
targeting efficiencies of CRISPR/Cas9 in somatic cells of domestic animals vary 
broadly with 9-70% in goat (NI et al., 2014) and 2.8-18% in pig (WHITWORTH et 
al., 2014) intending the KO of a gene and 32.2-80% in a gene knockin study with 
bovine cells (JEONG et al., 2016). In aforementioned studies, the high variation in 
efficiency relates to different cell lines (JEONG et al., 2016), the design of sgRNAs 
(WHITWORTH et al., 2014) or the targeting of different genes (NI et al., 2014). 
Therefore, a low CRISPR/Cas9 efficiency may be improved by testing different 
sgRNAs and cell lines, which was omitted in this study because the primary goal of 
producing a cell clone with a non-functional OCT4 gene was achieved with the first 
transfection. Interestingly, mutation frequency was highly increased at the ETF1 off-
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target site (36%), which may be due to a less condensed chromatin status when 
compared to OCT4. In mouse thymocytes, the histones H3 and H4 of Oct4 are 
hypoacetylated and lysine 4 of H3 (H3K4) is demethylated, leading to a silenced and 
condensed gene (KIMURA et al., 2004), while in pluripotent cells Oct4 is packaged 
with acetylated H3/H4 and H3K4 is methylated (CEDAR & BERGMAN, 2009). 
This leads to the assumption, that also in the somatic cell line WalterBF-Tg(PGK-
EGFP) used for transfection in this study, the OCT4 locus was condensed. With the 
protein encoded by ETF1 playing an essential role in termination of mRNA 
translation (KISSELEV et al., 2003), it is reasonable to suggest that it is active and 
therefore less condensed than OCT4 in all cell types. ISAAC et al. (2016) have 
shown, that action of Cas9 decreases with DNA packaged on nucleosomes and that 
chromatin remodelers can enhance Cas9 activity, which shows that CRISPR/Cas9 
efficiency is influenced by the chromatin status of the target gene. This interaction 
between targeting efficiency and chromatin status might explain the increased 
frequency of mutation events at the ETF1 locus when compared to OCT4.  
To study the role of OCT4 in bovine preimplantation development, embryos were 
reconstructed via SCNT from the above-mentioned cell clone (OCT4 KO) and from 
non-transfected cells of the same source as a control (NT CTRL). Despite the fusion 
rate of the enucleated oocyte with the donor cell, there were no differences in 
development between embryos reconstructed from OCT4 KO or NT CTRL cells 
until day 5 morula stage. The increased fusion rate with OCT4 KO cells might be due 
to an enlarged cell size when compared to cells from NT CTRL (data not shown), 
which facilitates contact between somatic cell and oocyte while applying the electric 
pulse for fusion. The development to blastocyst stage by day 7 was strongly 
decreased in OCT4 KO embryos when compared to NT CTRL (16.78 ± 10.21% vs.  
32.07 ± 10.84%) and typically, blastocyst rate after SCNT varies between 20-60% 
(TSUNODA et al., 2006). It remains unclear if this effect on developmental 
competence is related to the loss of OCT4 or to a cell clone specific artefact. It is 
known from several studies in mouse, that the loss of maternal and zygotic OCT4 
does not affect the number of homozygous Oct4 null blastocysts in the litters from 
heterozygously floxed Oct4 crosses, which remains at a Mendelian frequency of  
~ 25% (NICHOLS et al., 1998; FRUM et al., 2013; WU et al., 2013; LE BIN et al., 
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2014). Considering that Oct4 has no effect on blastocyst rate in mouse, the decreased 
developmental competence of bovine OCT4 KO embryos might be specific to the 
cell clone used in this study. Because besides inducing the biallelic deletion in the 
OCT4 gene, CRISPR/Cas9 also caused a mutation in ETF1. This off-target effect 
may decrease the blastocyst rate, although the mutation only consists of a single 
nucleotide on one allele and is located in the first intron of ETF1. In addition, the 
procedures involved in producing mutated single cell clones, which include 
transfection and single cell culture followed by many passages, can alter the cells’ 
properties. To examine the effect of both, the mutation in ETF1 and the cell culture 
procedures, a single cell clone with the exact same mutation in ETF1 and none in 
OCT4 from the same transfection experiment was identified (ETF1mut
2F11tm1
) and 
SCNT was performed. Unfortunately, results are inconclusive, as there was no 
significant difference in blastocyst rate, neither to OCT4 KO nor to NT CTRL 
embryos. Therefore, from this data it is impossible to conclude whether the 
decreased blastocyst rate in OCT4 KO embryos is a cell clone specific effect or due 
to the loss of OCT4.    
At day 7, there was no difference in morphology between OCT4 KO and NT CTRL 
embryos (Figure 13) and also none in the number of total cells (Table 10). This is in 
concordance to mouse Oct4 KO embryos, where day 3.5 (NICHOLS et al., 1998) or 
day 3.75 (FRUM et al., 2013) blastocysts also have no reduced total cell count. 
These developmental stages are equivalent to bovine day 7 and 8, i.e. blastocyst 
stage and beginning of hypoblast differentiation, respectively. While there was no 
difference in total cell number between embryos from nuclear transfer experiments at 
day 7, IVP CTRL embryos had an increased total cell count. KOO et al. (2002) 
reported no difference in total cell number between embryos from IVP and SCNT at 
day 7, whereas various studies did find an increased cell count in IVP embryos 
(SONG et al., 2011; BANG et al., 2015; CHEN et al., 2015). This indicates, although 
data from the literature is contradicting, that bovine SCNT embryos tend to have a 
generally lower cell count than IVP embryos and that the difference in this study is 
not related to the cells used for SCNT. By day 9, OCT4 KO embryos showed a 
marked decrease in size and total cell number when compared to controls. This is 
also reported for mouse day 4.25 Oct4 KO blastocysts (the developmental equivalent 
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to bovine day 9), where TE cells proliferated less than in controls and growth of ICM 
cells stagnated (FRUM et al., 2013). Differential staining of TE and ICM with the 
TE-specific marker CDX2 showed that day 7 OCT4 KO embryos have an unchanged 
percentage of TE cells when compared to NT CTRL and IVP CTRL embryos. Also, 
like in mouse day 3.5 blastocysts (WU et al., 2016), ICM cells did not stain positive 
for CDX2. This leads to the conclusion, that OCT4 is not required for the 
quantitative allocation of cells to either ICM or TE during the first lineage 
differentiation and that OCT4 does not repress CDX2 expression in the ICM. 
Therefore, other factors than OCT4 control the first differentiation event in bovine 
early preimplantation embryos and loss of OCT4 does not compromise the lineage 
segregation into ICM and TE, which coincides with the mouse Oct4 KO model.  
To confirm the absence of OCT4, embryos were subjected to immunofluorescent 
labeling of the protein. In control embryos (NT CTRL and IVP CTRL), OCT4 was 
expressed in all cells at day 5 morula stage. KHAN et al. (2012) reported that OCT4 
is not detectable in earlier stages, i.e. from oocyte until 8-cell stage. At the 16-cell 
stage, when embryonic genome activation (EGA) is complete, they found a slight 
signal and strong signals were only detectable from day 5 morula onward. 
Interestingly, OCT4 KO morulae at day 5 still expressed OCT4, albeit not in all 
nuclei and with decreased intensity. As embryonic OCT4 is non-functional, the 
detected OCT4 must have derived from maternal stores of the protein or mRNA in 
the oocyte. By day 7, all cells stained negative for OCT4 in OCT4 KO embryos, so 
maternal OCT4 had completely decayed, while control embryos ubiquitously 
expressed OCT4. With the NT CTRL embryos showing the same OCT4 expression 
pattern as the IVP CTRLs, i.e. expression in the ICM and co-expression with CDX2 
in the TE as reported previously (BERG et al., 2011), any effects of SCNT on timing 
and localization of OCT4 expression can be excluded.    
As mentioned above, expression of CDX2 at day 7 blastocyst stage was not affected 
by OCT4 KO. At day 5 morula stage, CDX2 was expressed in the cytoplasm and 
subsequently migrated to the nuclei of TE cells in all embryos. MADEJA et al. 
(2013) performed immunofluorescent stainings against CDX2 using the same 
antibody as in this study and found cytoplasmic expression until compacted morula 
stage, when CDX2 was also detected in the nuclei. Transition of CDX2 from 
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cytoplasm to nucleus is therefore most likely to occur during compaction, as day 5 
morulae examined here were not compacted yet. Another study reports no 
cytoplasmic expression and first detection of CDX2 at blastocyst stage when using 
an antibody with a different epitope (GOISSIS & CIBELLI, 2014), indicating that 
different isoforms of CDX2 may be present during preimplantation development and 
that further examination of the temporal and spatial expression of CDX2 in bovine is 
necessary.  
As developmental failure of Oct4 KO mouse embryos is connected to their inability 
to complete the second lineage differentiation (FRUM et al., 2013; LE BIN et al., 
2014), epiblast (EPI) and hypoblast (HB) segregation was observed in bovine OCT4 
KO embryos. By staining against the EPI and HB specific markers NANOG and 
GATA6 at days 5, 7 and 9, it was possible to determine the spatial and temporal 
expression patterns and to examine the effect of loss of OCT4 on the segregation of 
the second differentiated lineage (HB) and on the maintenance of the pluripotent EPI. 
At day 5 morula stage, NANOG and GATA6 co-expressed in the majority of cells, 
while in OCT4 KO embryos the percentage of GATA6 positive cells was 
significantly decreased. Reports on NANOG expression at morula stage are not 
consistent in the literature, e.g. KUIJK et al. (2012) reported no expression, KHAN 
et al. (2012) expression in the nucleolus and MADEJA et al. (2013) detected signals 
in the cytoplasm and rings around and the nuclei. When comparing results, it is 
important to take into account the exact developmental stage. Unfortunately, only 
KUIJK et al. (2012) further specified their material by stating the total cell count at 
time of examination (day 5) with 19.7 ± 6.9 while here it was 56.1 ± 12 in IVP 
CTRL embryos, without significant difference to embryos from SCNT. With 
increasing cell count at day 6 (39 ± 18.9), KUIJK et al. (2012) also found ubiquitous 
weak expression of NANOG. GRAF et al. (2014) determined the 8-cell stage as 
onset of embryonic NANOG transcription and found transcripts in all developmental 
stages until blastocyst stage. Additionally, blastomeres of mouse morulae also 
express NANOG before forming the blastocyst (CHAZAUD et al., 2006), therefore 
data from the literature make the results presented here plausible. Reports on GATA6 
expression in bovine morulae are scarce, however KUIJK et al. (2012) found the 
same pattern at day 6 with most nuclei staining positive. No data on NANOG and 
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GATA6 expression are available from the mouse Oct4 KO models at morula stage, 
which makes it difficult to speculate, why the percentage of GATA6 positive 
blastomeres in OCT4 KO morulae was significantly decreased.   
At day 7, a salt and pepper distribution of NANOG and GATA6 was already visible 
within the ICM of control embryos. Nevertheless, expression was not yet mutually 
exclusive and cells from the TE still stained positive for both markers. The same 
staining pattern for NANOG and GATA6 in day 7 bovine blastocysts has been 
reported previously (KHAN et al., 2012; KUIJK et al., 2012; DENICOL et al., 
2014). Remarkably, OCT4 KO embryos did not express any NANOG by day 7, but 
still contained cells that stained positive for GATA6 in a similar pattern as in the 
controls. This is especially interesting in the light of the disturbed second lineage 
differentiation in mouse Oct4 KO embryos, where ICM cells at day 3.5-3.75 still 
show the same distribution of EPI and primitive endoderm (PE, the equivalent to 
bovine hypoblast) precursor cells. At day 4.25, the ICM contains no more GATA6 
positive cells but NANOG is still present (FRUM et al., 2013; LE BIN et al., 2014), 
which is completely opposite to the bovine OCT4 KO phenotype observed in this 
study. In mouse, the current working model of PE differentiation (Figure 3) states, 
that OCT4 regulates FGF4 expression to induce PE cell fate and additionally 
activates PE genes in PE precursor cells (FRUM et al., 2013). In bovine blastocysts 
depleted of FGF4 signaling, GATA6 expression is still maintained and therefore not 
FGF4 dependent (KUIJK et al., 2012), which might explain the unchanged 
expression of GATA6 in OCT4 KO day 7 blastocysts. NANOG expression at morula 
stage is unchanged in OCT4 KO embryos and also derived from de novo transcripts, 
as there are no maternal NANOG mRNA stores in the oocyte (GRAF et al., 2014) 
and the half-life of NANOG protein is ~ 3 h in mouse and human embryonic stem 
cells (HAYASHI et al., 2015). This suggests that initiation of NANOG expression 
and maintenance until morula stage is not OCT4 dependent, but during the first 
lineage differentiation NANOG is lost, so its expression in the ICM and therefore 
EPI maintenance requires OCT4.  
By day 9, OCT4 KO embryos had also lost GATA6 expression, while in controls 
expression of EPI and HB markers was limited to the ICM and mutually exclusive. 
Unfortunately, embryos cultured in vitro until day 9 had many degenerated nuclei, 
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which made further analysis of differentiation events futile. Mouse embryos are 
flushed from the uterus at any time point before implantation, i.e. until day 4.25, 
when PE differentiation is already complete (NAGY et al., 2003). To be able to 
thoroughly study the effects of OCT4 KO on the second lineage differentiation in 
bovine embryos, day 9 embryos need to be produced without artefacts from in vitro 
culture, which can be achieved by either improving culture conditions or by transfer 
of embryos to recipients and flushing them non-surgically at day 9. This would 
provide authentic material to investigate the mechanisms during second lineage 
differentiation, which apparently differ substantially from the lessons learned with 
the mouse model. Knowledge about the interactions between the transcription factors 
that regulate pluripotency and first differentiation events might also help understand, 
why the establishment of embryonic stem cell lines in bovine is still unsuccessful. 
Additionally, human preimplantation development resembles bovine more than 
mouse in many aspects, i.e. the interaction between OCT4 and CDX2 (BERG et al., 
2011) and the role of FGF4/MAPK signaling (KUIJK et al., 2012; ROODE et al., 
2012), which might render bovine preimplantation embryos the better model to study 
human development.        
Wild-type donor blastomeres do not populate the ICM in chimeras with OCT4 
KO host embryos 
To test the hypothesis that due to their deficient pluripotency network, cells from an 
OCT4 KO host embryo differentiate into extraembryonic tissues while wild-type 
donor blastomeres populate the ICM within a chimera, two day 4 OCT4 KO host 
morulae were subjected to synchronic aggregation with four blastomeres from a 
wild-type morula. Blastocyst rate of aggregated chimeras markedly increased when 
compared to single OCT4 KO embryos (74% vs. 17%, respectively), showing a 
positive effect of aggregation on development as shown before in bovine embryos 
from SCNT (BANG et al., 2015). The developmental kinetics did not change and 
chimeras without OCT4 showed compaction of the aggregation partners to one single 
morula before development of the blastocoel, suggesting that these mechanisms are 
independent of OCT4. Nevertheless, chimeras with OCT4 KO hosts had expanded 
less 96 h after aggregation when compared to wild-type chimeras, which is analog to 
single day 9 hatched OCT4 KO blastocyst.  
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Developed blastocysts were stained against OCT4 and CDX2 and analyzed using 
CLSM. In 7 out of 13 blastocysts, donor blastomeres integrated to the chimera and 
surprisingly mainly differentiated into TE cells, while cells from the OCT4 KO hosts 
were found in the ICM of every analyzed blastocyst. In asynchronic wild-type 
chimeras, the percentage of blastocysts with donor cells in the TE was only 1.2%, 
showing a clear tendency of the developmentally advanced donor cells towards the 
ICM. With OCT4 KO hosts, embryos were subjected to synchronic aggregation to 
study the effect of an OCT4 deficiency on lineage segregation; therefore, data from 
the two experiments are not comparable. However, HIRIART et al. (2013) compared 
synchronic and asynchronic aggregation and found a higher contribution of donor 
cells to the ICM in the latter, suggesting that the developmental stages of host and 
donor influence their lineage allocation and that contribution of donor cells to the 
ICM could also be improved in OCT4 KO chimeras using developmentally advanced 
donor cells. Nevertheless, loss of OCT4 did not drive the host embryos into TE 
differentiation, once again stretching the embryo’s independence from OCT4 during 
the first lineage segregation. By injection of embryonic stem cells (ESCs) to 8-cell 
stage mouse embryos, fetuses completely derived from ESCs can be produced, 
because the injected cells colonize the ICM (POUEYMIROU et al., 2007). FRUM et 
al. (2013) injected ESCs to Oct4 KO mouse embryos to examine, if the wild-type 
cells can rescue the Oct4 KO phenotype. In these chimeras, contribution of ESCs did 
not differ between wild-type and Oct4 KO hosts and the donor cells colonized the 
ICM. Therefore, in mouse, allocation of donor and host to the cell lineages in the 
chimeric blastocyst is not affected by a OCT4 deficient host. The experiments also 
showed, that OCT4 is required cell-autonomously for the second lineage 
differentiation of the primitive endoderm, which is why the injected ESCs were not 
able to rescue the Oct4 KO phenotype. It remains unclear, why the wild-type 
blastomeres in bovine OCT4 KO chimeras mainly contributed to the TE. Further 
experiments are necessary to evaluate the effects of synchronic vs. asynchronic 
aggregation and additionally, stochastic effects at the first lineage differentiation are 
to be excluded by aggregation of an equal amount of wild-type and OCT4 KO cells. 
Also, by aggregation of previously disaggregated OCT4 KO and wild-type 
blastomeres, random position inside or outside the chimeric morula can be ensured 
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and bias in allocation to the TE or ICM resulting from the former location in the 
morula is prevented. Given this additional data, it may be possible to clarify whether 
differentiation of wild-type blastomeres to TE cells in OCT4 KO chimeras is due an 
unknown mechanism involving TE differentiation and OCT4, or if the effects seen 
here are of different nature. The clear and stable eGFP expression of cells derived 
from the OCT4 KO hosts makes the established system perfect for further 
investigations.   
The approach to use OCT4 KO embryos in a biotechnological context to multiply 
elite embryos is fruitless, because aggregation with a few wild-type cells did not 
have the anticipated effect, that those cells would primarily colonize the ICM and 
give rise to the embryo proper. Although it is ensured that the OCT4 KO hosts lose 
all pluripotency due to the loss of NANOG at day 7 and therefore are not capable of 
contribution to the fetus, donor cells integrated poorly to the ICM and furthermore 
predominantly differentiated to TE cells. The approach presented also includes 
SCNT for the production of the OCT4 KO hosts, because this is the only possible 
way to provide definite OCT4 KO embryos before aggregation. Injection of 
CRISPR/Cas9 to zygotes would be a technically less demanding alternative, but until 
now there is no possibility to monitor if OCT4 was knocked out before aggregating 
the chimera. Therefore, multiplication of embryos using chimeric complementation 
with OCT4 KO host embryos is neither efficient nor technically undemanding.  
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VI. Summary 
Chimeric bovine embryo multiplication with OCT4 knockout host embryos  
With the advent of genomic selection and the possibility to select superior genotypes 
on the embryonic level, the commercial value of individual embryos has increased 
and therefore, the multiplication of elite bovine embryos is of great interest. 
Available techniques, like embryonic cell nuclear transfer or blastomere separation to 
produce monozygotic twins, have not been implemented due to high technical 
demand or low efficiencies. The multiplication of elite embryos by the production of 
aggregation chimeras is based on the concept that few blastomeres of a donor 
embryo form the inner cell mass (ICM), whereas host embryo cells preferentially 
contribute to the trophectoderm (TE). Later in development, cells from the ICM will 
give rise to the fetus, while TE cells form the embryonic part of the placenta, so 
resulting offspring exclusively carries the donor’s genotype. The biggest challenge in 
this technique is to find ways to exclude host embryo cells from the ICM in the 
chimeric blastocyst, while potential advantages are a high efficiency regarding 
transferable blastocysts and a low technical demand.   
In this thesis, I first tested wild-type embryos that did not complete their first 
cleavage until 27 h after fertilization as host embryos and additionally evaluated the 
effect of phytohemagglutinin (PHA), a membrane protein binding agent, on the 
development of aggregation chimeras. The use of PHA highly increased the 
blastocyst rate and enabled stable positioning of the aggregation partners within the 
chimera. This increased the integration of donor blastomeres to the ICM, probably 
because their position was fixed in between the host embryos so they eventually 
migrated to the inside of the emerging morula, where they are more likely to 
contribute to the ICM. Nevertheless, this approach did not provide sufficient 
segregation of donor and host into the different cell lineages to be suitable for the 
multiplication of genetically valuable embryos.  
The rationale to use an OCT4 knockout (KO) embryo as host in chimeric 
multiplication was to ensure its absolute exclusion from potential offspring. OCT4 is 
on top of the pluripotency hierarchy and OCT4 deficient blastomeres from the host 
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embryo cannot maintain their pluripotent state and thus do not contribute to the 
embryo proper, but form extraembryonic tissues to support the few donor cells. To 
test this hypothesis, OCT4 was knocked out in somatic cells using CRISPR/Cas9 and 
embryos were subsequently reconstructed with somatic cell nuclear transfer. Because 
this is, to my knowledge, the first report on OCT4 KO in bovine embryos, the KO 
phenotype was examined before performing chimera aggregation experiments. In 
conclusion, OCT4 KO does not affect the total cell number or quantitative allocation 
of cells to ICM or TE by day 7 blastocyst stage, but the epiblast specific marker 
NANOG is already lost. This is in contrast to the development of mouse Oct4 KO 
embryos, where NANOG expression is maintained, indicating substantial differences 
between mouse and bovine in the regulation of the second lineage differentiation.  
In chimeras from OCT4 KO host embryos and wild-type donor cells, the donor cells 
did not, as anticipated, colonize the ICM, but predominantly differentiated into TE 
cells. It remains unclear why the wild-type blastomeres in bovine OCT4 KO 
chimeras mainly contributed to the TE and if there is an underlying mechanism 
involving TE differentiation and OCT4 that caused the wild-type cells to mainly 
contribute to this lineage. In conclusion, the KO of OCT4 would exclude the hosts’ 
cells from the embryo proper due to the early loss of NANOG, but the poor 
contribution of donor cells to the ICM of the chimeras makes the proposed method 
for multiplication of elite embryos infeasible.      
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VII. Zusammenfassung 
Multiplikation von Rinderembryonen durch Chimärenbildung mit OCT4 
knockout Embryonen  
Mit dem Aufkommen der genomischen Selektion und der Möglichkeit züchterisch 
wertvolle Genotypen bereits im embryonalen Stadium zu identifizieren, ist der 
kommerzielle Wert einzelner Embryonen gestiegen, weshalb die Multiplikation von 
Rinderembryonen von großem Interesse ist. Bereits verfügbare Methoden wie z.B. 
Kerntransfer embryonaler Zellen oder das Zerteilen von Embryonen, um 
monozygote Zwillinge zu produzieren, werden derzeit wegen ihrem hohen 
technischen Anspruch oder geringer Effizienz nicht durchgeführt. Die Multiplikation 
wertvoller Embryonen mittels Chimären-Aggregation beruht auf der Idee, dass 
wenige Zellen dieser Embryonen, sog. Spenderzellen, die innere Zellmasse (inner 
cell mass, ICM) bilden, während Empfängerembryonen das Trophektoderm (TE) 
bilden. In der weiteren Entwicklung entsteht der Fötus aus den Zellen der ICM und 
das TE entwickelt sich weiter zum embryonalen Bestandteil der Plazenta, so dass 
Nachkommen ausschließlich den Genotyp des positiv selektierten Embryos tragen. 
Die größte Herausforderung bei dieser Methode besteht darin, Wege zu finden, 
Empfängerembryonen von der ICM auszuschließen. Die Vorteile liegen bei einer 
hohen Effizienz hinsichtlich übertragbarer Embryonen und einem geringen 
technischen Anspruch.  
In dieser Arbeit wurden zuerst Wildtyp-Embryonen, die ihre erste Zellteilung nicht 
vor 27 h nach Befruchtung abgeschlossen hatten, als Empfängerembryonen getestet. 
Zusätzlich wurde der Einsatz von Phytohämagglutinin (PHA), ein Mittel das 
Membranproteine aneinander bindet, bei der Aggregation der Embryonen geprüft. 
Mit PHA konnte die Blastozystenrate erheblich gesteigert werden, außerdem wurden 
die Positionen der Aggregationspartner in der Chimäre nachhaltig bestimmt. 
Dadurch wurde die Integration von Spenderzellen in die ICM erhöht, was 
möglicherweise darauf zurückzuführen ist, dass die Spenderzellen zwischen den 
Empfängerembryonen platziert wurden. In der Morula, die nach Aggregation 
entsteht, befanden sich die Spenderzellen dann eventuell im Inneren, was die 
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Wahrscheinlichkeit sich zur ICM zu entwickeln verbessert. Nichtsdestotrotz ergab 
sich bei dieser Methode nicht genügend Trennung zwischen Spender- und 
Empfängerzellen, so dass sich Empfängerzellen noch immer in der ICM befanden. 
Dadurch ist diese Multiplikationsmethode für genetisch wertvolle Embryonen 
ungeeignet. 
Um auf sichere Art und Weise Empfängerembryonen von der ICM auszuschließen, 
wurden Empfängerembryonen mit einem ausgeschalteten OCT4 Gen hergestellt 
(OCT4 knockout, KO). OCT4 steht an der Spitze der Pluripotenzregulation, weshalb 
Zellen mit einem OCT4 KO ihre Pluripotenz nicht erhalten und so auch nicht Teil 
des entstehenden Embryos werden können. Vielmehr entwickeln sie 
extraembryonale Gewebe und unterstützen so die wenigen Zellen des 
Spenderembryos. Um diese Hypothese zu prüfen, wurde OCT4 in somatischen 
Zellen mittels CRISPR/Cas9 ausgeschaltet, um dann durch somatischen 
Zellkerntransfer OCT4 KO Embryonen herzustellen. Bislang ist das die erste Studie, 
die den Effekt eines OCT4 KO bei Rinderembryonen untersucht, weshalb vor den 
Aggregationsexperimenten der Phänotyp dieser Embryonen beschrieben wurde. 
Zusammenfassend hat ein OCT4 KO weder Einfluss auf die Gesamtzellzahl noch auf 
die Zellzahlen der ICM oder des TE in der Blastozyste am Tag 7 der Entwicklung. 
Jedoch ist in diesem Stadium der Epiblast spezifische Marker NANOG nicht mehr 
vorhanden. Dies steht im Gegensatz zur Entwicklung von Maus Oct4 KO 
Embryonen, bei denen die Expression von NANOG erhalten bleibt. Dies zeigt 
wiederum grundlegende Unterschiede zwischen den Spezies während der zweiten 
Zelldifferenzierung auf.  
In den Chimären, die aus OCT4 KO Embryonen und Wildtyp-Spenderzellen 
hergestellt wurden, bestand die ICM nicht wie erwartet aus Spenderzellen, sondern 
differenzierten hauptsächlich zu Zellen des TE. Die Gründe für diese Entwicklung 
sind unbekannt; auch die Frage, ob es einen zugrundeliegenden Mechanismus gibt, 
der OCT4 und die Entstehung des TE beinhaltet und diese Differenzierung 
verursacht, bleibt ungeklärt. Grundsätzlich würde ein OCT4 KO die Beteiligung der 
Empfängerembryonen am Fötus durch den frühen Verlust von NANOG verhindern, 
allerdings macht die ungenügende Besiedelung der ICM durch Spenderzellen die 
Durchführung dieser Embryomultiplikationsmethode unmöglich. 
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